



US010542909B2

(12) **United States Patent**  
**Zdeblick et al.**

(10) **Patent No.:** **US 10,542,909 B2**  
(45) **Date of Patent:** **Jan. 28, 2020**

(54) **COMMUNICATION SYSTEM WITH  
PARTIAL POWER SOURCE**

(71) Applicant: **Proteus Digital Health, Inc.**, Redwood  
City, CA (US)

(72) Inventors: **Mark Zdeblick**, Portola Valley, CA  
(US); **Timothy Robertson**, Belmont,  
CA (US); **Aleksandr Pikelnny**, Los  
Angeles, CA (US); **Hooman Hafezi**,  
Redwood City, CA (US)

(73) Assignee: **Proteus Digital Health, Inc.**, Redwood  
City, CA (US)

(\*) Notice: Subject to any disclaimer, the term of this  
patent is extended or adjusted under 35  
U.S.C. 154(b) by 0 days.

(21) Appl. No.: **15/474,811**

(22) Filed: **Mar. 30, 2017**

(65) **Prior Publication Data**

US 2017/0265813 A1 Sep. 21, 2017

**Related U.S. Application Data**

(63) Continuation of application No. 14/865,508, filed on  
Sep. 25, 2015, now Pat. No. 9,649,066, which is a  
(Continued)

(51) **Int. Cl.**  
**A61B 5/07** (2006.01)  
**A61B 5/00** (2006.01)  
(Continued)

(52) **U.S. Cl.**  
CPC ..... **A61B 5/073** (2013.01); **A61B 5/0028**  
(2013.01); **A61B 5/0031** (2013.01); **A61B 5/07**  
(2013.01);  
(Continued)

(58) **Field of Classification Search**

CPC ... A61B 5/6861; A61B 5/7282; A61B 5/1473;  
A61B 5/681; A61B 5/4833; A61B 5/07;  
(Continued)

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

1,548,459 A 8/1925 Hammer  
2,587,158 A 2/1952 Hofberg  
(Continued)

**FOREIGN PATENT DOCUMENTS**

CN 1588649 3/2005  
CN 1650844 8/2005  
(Continued)

**OTHER PUBLICATIONS**

AADE, "AADE 37th Annual Meeting San Antonio Aug. 4-7, 2010"  
American Association of Diabetes Educators (2010); [http://www.  
diabeteseducator.org/annualmeeting/2010/index.html](http://www.diabeteseducator.org/annualmeeting/2010/index.html); 2 pp.

(Continued)


*Primary Examiner* — Brian Wilson

(74) *Attorney, Agent, or Firm* — K&L Gates LLP

(57) **ABSTRACT**

The system of the present invention includes a conductive  
element, an electronic component, and a partial power  
source in the form of dissimilar materials. Upon contact with  
a conducting fluid, a voltage potential is created and the  
power source is completed, which activates the system. The  
electronic component controls the conductance between the  
dissimilar materials to produce a unique current signature.  
The system can be used in a variety of different applications,  
including as components of ingestible identifiers, such as  
may be found in ingestible event markers, e.g., pharma-  
informatics enabled pharmaceutical compositions.

**18 Claims, 3 Drawing Sheets**



**Related U.S. Application Data**

continuation of application No. 14/341,639, filed on Jul. 25, 2014, now abandoned, which is a continuation of application No. 13/153,312, filed on Jun. 3, 2011, now Pat. No. 8,816,847, which is a continuation of application No. 12/564,017, filed on Sep. 21, 2009, now Pat. No. 7,978,064, which is a continuation of application No. 11/912,475, filed as application No. PCT/US2006/016370 on Apr. 28, 2006, now Pat. No. 8,847,766.

- (60) Provisional application No. 60/676,145, filed on Apr. 28, 2005, provisional application No. 60/694,078, filed on Jun. 24, 2005, provisional application No. 60/713,680, filed on Sep. 1, 2005, provisional application No. 60/790,335, filed on Apr. 7, 2006.

(51) **Int. Cl.**

*H01Q 1/27* (2006.01)  
*A61J 3/00* (2006.01)  
*G06K 7/10* (2006.01)  
*A61B 5/1473* (2006.01)

(52) **U.S. Cl.**

CPC ..... *A61B 5/076* (2013.01); *A61B 5/1473* (2013.01); *A61B 5/4833* (2013.01); *A61B 5/4839* (2013.01); *A61B 5/681* (2013.01); *A61B 5/6861* (2013.01); *A61B 5/7282* (2013.01); *A61J 3/007* (2013.01); *G06K 7/10168* (2013.01); *H01Q 1/273* (2013.01); *A61B 2560/0214* (2013.01); *A61B 2560/0462* (2013.01); *A61B 2562/08* (2013.01); *A61B 2562/162* (2013.01); *Y10T 29/49117* (2015.01)

(58) **Field of Classification Search**

CPC ..... *A61B 5/0028*; *A61B 5/0031*; *A61B 5/073*; *A61B 5/4839*; *A61B 2560/0214*; *A61B 2562/08*; *A61B 2562/162*; *A61B 2560/0462*; *A61B 5/076*; *G06K 7/10168*; *H01Q 1/273*; *A61J 3/007*; *Y10T 29/49117*; *G06F 19/00*

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,973,555 A 3/1961 Schwepke  
 3,048,526 A 8/1962 Boswell  
 3,079,824 A 3/1963 Schott  
 3,096,248 A 7/1963 Rudzki  
 3,176,399 A 4/1965 Marino et al.  
 3,589,943 A 6/1971 Grubb et al.  
 3,607,788 A 9/1971 Adolph  
 3,642,008 A 2/1972 Bolduc  
 3,679,480 A 7/1972 Brown et al.  
 3,682,160 A 8/1972 Murata  
 3,719,183 A 3/1973 Schwartz  
 3,799,802 A 3/1974 Schneble, Jr. et al.  
 3,828,766 A 8/1974 Krasnow  
 3,837,339 A 9/1974 Aisenberg et al.  
 3,849,041 A 11/1974 Knapp  
 3,893,111 A 7/1975 Cotter  
 3,944,064 A 3/1976 Bashaw et al.  
 3,967,202 A 6/1976 Batz  
 3,989,050 A 11/1976 Buchalter  
 4,017,856 A 4/1977 Wiegand  
 4,055,178 A 10/1977 Harrigan  
 4,062,750 A 12/1977 Butler  
 4,077,397 A 3/1978 Ellis  
 4,077,398 A 3/1978 Ellis  
 4,082,087 A 4/1978 Howson

4,090,752 A 5/1978 Long  
 4,106,348 A 8/1978 Auphan  
 4,129,125 A 12/1978 Lester  
 4,139,589 A 2/1979 Beringer et al.  
 4,143,770 A 3/1979 Grimmell et al.  
 4,166,453 A 9/1979 McClelland  
 4,239,046 A 12/1980 Ong  
 4,251,795 A 2/1981 Shibasaki et al.  
 4,269,189 A 5/1981 Abraham  
 4,331,654 A 5/1982 Morris  
 4,345,588 A 8/1982 Widder et al.  
 4,418,697 A 12/1983 Tama  
 4,425,117 A 1/1984 Hugemann  
 4,439,196 A 3/1984 Higuchi  
 4,494,950 A 1/1985 Fischell  
 4,559,950 A 12/1985 Vaughan  
 4,564,363 A 1/1986 Bagnall et al.  
 4,635,641 A 1/1987 Hoffman  
 4,654,165 A 3/1987 Eisenber  
 4,663,250 A 5/1987 Ong et al.  
 4,669,479 A 6/1987 Dunseath  
 4,687,660 A 8/1987 Baker et al.  
 4,725,997 A 2/1988 Urquhart et al.  
 4,749,575 A 6/1988 Rotman et al.  
 4,763,659 A 8/1988 Dunseath  
 4,767,627 A 8/1988 Caldwell et al.  
 4,775,536 A 10/1988 Patell  
 4,784,162 A 11/1988 Ricks  
 4,793,825 A 12/1988 Benjamin et al.  
 4,814,181 A 3/1989 Jordan et al.  
 4,844,076 A 7/1989 Lesho  
 4,847,090 A 7/1989 Della Posta et al.  
 4,876,093 A 10/1989 Theeuwes et al.  
 4,891,223 A 1/1990 Ambegaonakar et al.  
 4,896,261 A 1/1990 Nolan  
 4,900,552 A 2/1990 Sanvordeker et al.  
 4,975,230 A 12/1990 Pinkhasov  
 4,987,897 A 1/1991 Funke  
 5,000,957 A 3/1991 Eckenhoff et al.  
 5,016,634 A 5/1991 Vock et al.  
 5,018,335 A 5/1991 Yamamoto et al.  
 5,079,006 A 1/1992 Urquhart  
 5,110,441 A 5/1992 Kinlen et al.  
 5,160,885 A 11/1992 Hannam et al.  
 5,167,626 A 12/1992 Casper  
 5,176,626 A 1/1993 Soehendra  
 5,187,723 A 2/1993 Mueller  
 5,213,738 A 5/1993 Hampton et al.  
 5,218,343 A 6/1993 Stobbe et al.  
 5,261,402 A 11/1993 DiSabito  
 5,263,481 A 11/1993 Axelgaard et al.  
 5,273,066 A 12/1993 Graham et al.  
 5,279,607 A 1/1994 Schentag et al.  
 5,281,287 A 1/1994 Lloyd  
 5,283,136 A 2/1994 Peled et al.  
 5,288,564 A 2/1994 Klein  
 5,305,745 A 4/1994 Zacouto  
 5,310,301 A 5/1994 Aono  
 5,318,557 A 6/1994 Gross  
 5,331,953 A 7/1994 Andersson et al.  
 5,394,882 A 3/1995 Mawhinney  
 5,395,366 A 3/1995 D'Andrea et al.  
 5,436,091 A 7/1995 Shackle et al.  
 5,443,461 A 8/1995 Atkinson et al.  
 5,443,843 A 8/1995 Curatolo et al.  
 5,458,141 A 10/1995 Neil et al.  
 5,458,994 A 10/1995 Nesselbeck et al.  
 5,485,841 A 1/1996 Watkin et al.  
 5,506,248 A 4/1996 Nikfar et al.  
 5,551,020 A 8/1996 Flax et al.  
 5,567,210 A 10/1996 Bates et al.  
 5,596,302 A 1/1997 Mastrocola et al.  
 5,600,548 A 2/1997 Nguyen et al.  
 5,603,363 A 2/1997 Nelson  
 5,634,468 A 6/1997 Platt  
 5,645,063 A 7/1997 Straka et al.  
 5,659,247 A 8/1997 Clements  
 5,703,463 A 12/1997 Smith  
 5,705,189 A 1/1998 Lehmann et al.

(56)

## References Cited

## U.S. PATENT DOCUMENTS

5,724,432 A	3/1998	Bouvet et al.	6,602,518 B2	8/2003	Seielstad et al.
5,738,708 A	4/1998	Peachey et al.	6,605,038 B1	8/2003	Teller
5,740,811 A	4/1998	Hedberg	6,609,018 B2	8/2003	Cory
5,757,326 A	5/1998	Koyama et al.	6,612,984 B1	9/2003	Kerr
5,772,575 A	6/1998	Lesinski et al.	6,632,175 B1	10/2003	Marshall
5,792,048 A	8/1998	Schaefer	6,632,216 B2	10/2003	Houzego et al.
5,802,467 A	9/1998	Salazar	6,635,279 B2	10/2003	Kolter et al.
5,833,716 A	11/1998	Bar-Or	6,643,541 B2	11/2003	Mok et al.
5,842,324 A	12/1998	Grosskopf et al.	6,654,638 B1	11/2003	Sweeney
5,845,265 A	12/1998	Woolston	6,663,846 B1	12/2003	McCombs
5,862,803 A	1/1999	Besson	6,673,474 B2	1/2004	Yamamoto
5,868,136 A	2/1999	Fox	6,680,923 B1	1/2004	Leon
5,914,132 A *	6/1999	Kelm ..... A61K 9/145 424/467	6,689,117 B2	2/2004	Sweeney et al.
5,914,701 A	6/1999	Gersheneld et al.	6,694,161 B2	2/2004	Mehrotra
5,925,030 A	7/1999	Gross et al.	6,704,602 B2	3/2004	Berg et al.
5,957,854 A	9/1999	Besson et al.	6,720,923 B1	4/2004	Hayward et al.
5,963,132 A	10/1999	Yoakum et al.	6,738,671 B2	5/2004	Christophersom et al.
5,974,124 A	10/1999	Schlueter, Jr. et al.	6,740,033 B1	5/2004	Olejniczak et al.
5,981,166 A	11/1999	Mandecki	6,745,082 B2	6/2004	Axelgaard et al.
5,999,846 A	12/1999	Pardey et al.	6,755,783 B2	6/2004	Cosentino
6,018,229 A	1/2000	Mitchell et al.	6,757,523 B2	6/2004	Fry
6,038,464 A	3/2000	Axelgaard et al.	6,759,968 B2	7/2004	Zierolf
6,042,710 A	3/2000	Dubrow	6,767,200 B2	7/2004	Sowden et al.
6,047,203 A	4/2000	Sackner	6,773,429 B2	8/2004	Sheppard et al.
6,068,465 A	5/2000	Wilson	6,800,060 B2	10/2004	Marshall
6,068,589 A	5/2000	Neukermans	6,801,137 B2	10/2004	Eggers et al.
6,076,016 A	6/2000	Feierbach et al.	6,816,794 B2	11/2004	Alvi
6,081,734 A	6/2000	Batz	6,822,554 B2	11/2004	Vrijens et al.
6,091,975 A	7/2000	Daddona et al.	6,824,512 B2	11/2004	Warkentin et al.
6,095,985 A	8/2000	Raymond et al.	6,836,862 B1	12/2004	Erekson et al.
6,115,636 A	9/2000	Ryan	6,839,659 B2	1/2005	Tarassenko et al.
6,122,351 A	9/2000	Schlueter, Jr. et al.	6,840,904 B2	1/2005	Goldberg
6,141,592 A	10/2000	Pauly	6,842,636 B2	1/2005	Perrault
6,149,940 A	11/2000	Maggi et al.	6,845,272 B1	1/2005	Thomsen
6,200,265 B1	3/2001	Walsh et al.	6,864,780 B2	3/2005	Doi
6,206,702 B1	3/2001	Hayden et al.	6,879,810 B2	4/2005	Bouet
6,217,744 B1	4/2001	Crosby	6,888,337 B2	5/2005	Sawyers
6,231,593 B1	5/2001	Meserol	6,889,165 B2	5/2005	Lind et al.
6,245,057 B1	6/2001	Sieben et al.	6,909,878 B2	6/2005	Haller
6,269,058 B1	7/2001	Yamanoi et al.	6,922,592 B2	7/2005	Thompson et al.
6,285,897 B1	9/2001	Kilcoyne et al.	6,928,370 B2	8/2005	Anuzis et al.
6,287,252 B1	9/2001	Lugo	6,929,636 B1	8/2005	Von Alten
6,288,629 B1	9/2001	Cofino et al.	6,937,150 B2	8/2005	Medema
6,289,238 B1	9/2001	Besson et al.	6,942,616 B2	9/2005	Kerr
6,315,719 B1	11/2001	Rode et al.	6,942,770 B2	9/2005	Cai et al.
6,317,714 B1	11/2001	Del Castillo	6,951,536 B2	10/2005	Yokoi
6,342,774 B1	1/2002	Kreisinger et al.	6,957,107 B2	10/2005	Rogers et al.
6,344,824 B1	2/2002	Takasugi et al.	6,958,603 B2	10/2005	Kondo
6,358,202 B1	3/2002	Arent	6,960,617 B2	11/2005	Omidian et al.
6,364,834 B1	4/2002	Reuss	6,968,153 B1	11/2005	Heinonen
6,366,206 B1	4/2002	Ishikawa et al.	6,977,511 B2	12/2005	Patel et al.
6,371,927 B1	4/2002	Brune	6,982,094 B2	1/2006	Sowden
6,374,670 B1	4/2002	Spelman	6,987,965 B2	1/2006	Ng et al.
6,380,858 B1	4/2002	Yarin et al.	6,990,082 B1	1/2006	Zehavi et al.
6,390,088 B1	5/2002	Noehl et al.	7,002,476 B2	2/2006	Rapchak
6,394,997 B1	5/2002	Lemelson	7,004,395 B2	2/2006	Koenck
6,426,863 B1	7/2002	Munshi	7,009,634 B2	3/2006	Iddan et al.
6,432,292 B1	8/2002	Pinto et al.	7,009,946 B1	3/2006	Kardach
6,440,069 B1	8/2002	Raymond et al.	7,013,162 B2	3/2006	Gorsuch
6,441,747 B1	8/2002	Khair	7,016,648 B2	3/2006	Haller
6,453,199 B1	9/2002	Kobozev	7,020,508 B2	3/2006	Stivorice
6,477,424 B1	11/2002	Thompson et al.	7,024,248 B2	4/2006	Penner et al.
6,496,705 B1	12/2002	Ng et al.	7,031,745 B2	4/2006	Shen
6,526,315 B1	2/2003	Inagawa	7,031,857 B2	4/2006	Tarassenko et al.
6,531,026 B1	3/2003	Takeichi et al.	7,039,453 B2	5/2006	Mullick
6,544,174 B2	4/2003	West	7,044,911 B2	5/2006	Drinan et al.
6,547,994 B1	4/2003	Monkhouse et al.	7,046,649 B2	5/2006	Awatere et al.
6,564,079 B1	5/2003	Cory	7,061,236 B2	6/2006	Britton
6,567,685 B2	5/2003	Takamori et al.	7,083,578 B2	8/2006	Lewkowicz
6,572,636 B1	6/2003	Hagen et al.	7,116,252 B2	10/2006	Teraguchi
6,577,893 B1	6/2003	Besson	7,118,531 B2	10/2006	Krill
6,579,231 B1	6/2003	Phipps	7,122,143 B2	10/2006	Sowden et al.
6,595,929 B2	7/2003	Stivorice	7,127,300 B2	10/2006	Mazar et al.
6,599,284 B2	7/2003	Faour et al.	7,146,228 B2	12/2006	Nielsen
			7,146,449 B2	12/2006	Do et al.
			7,149,581 B2	12/2006	Goedeke
			7,154,071 B2	12/2006	Sattler et al.
			7,155,232 B2	12/2006	Godfrey et al.
			7,160,258 B2	1/2007	Imran

(56)

## References Cited

## U.S. PATENT DOCUMENTS

7,164,942 B2	1/2007	Avrahami	7,525,426 B2	4/2009	Edelstein
7,171,166 B2	1/2007	Ng et al.	7,537,590 B2	5/2009	Santini, Jr. et al.
7,171,177 B2	1/2007	Park et al.	7,539,533 B2	5/2009	Tran
7,171,259 B2	1/2007	Rytky	7,542,878 B2	6/2009	Nanikashvili
7,176,784 B2	2/2007	Gilbert et al.	7,547,278 B2	6/2009	Miyazaki et al.
7,187,960 B2	3/2007	Abreu	7,551,590 B2	6/2009	Haller
7,188,199 B2	3/2007	Leung et al.	7,554,452 B2	6/2009	Cole
7,188,767 B2	3/2007	Penuela	7,558,620 B2	7/2009	Ishibashi
7,194,038 B1	3/2007	Inkinen	7,575,005 B2	8/2009	Mumford
7,196,495 B1	3/2007	Burcham	7,616,111 B2	11/2009	Covannon
7,206,630 B1	4/2007	Tarler	7,617,001 B2	11/2009	Penner et al.
7,209,790 B2	4/2007	Thompson et al.	7,626,387 B2	12/2009	Adachi
7,215,660 B2	5/2007	Perlman	7,639,473 B2	12/2009	Hsu et al.
7,215,991 B2	5/2007	Besson	7,640,802 B2	1/2010	King et al.
7,218,967 B2	5/2007	Bergelson	7,645,262 B2	1/2010	Greenberg et al.
7,231,451 B2	6/2007	Law	7,647,112 B2	1/2010	Tracey
7,243,118 B2	7/2007	Lou	7,647,185 B2	1/2010	Tarassenko et al.
7,246,521 B2	7/2007	Kim	7,653,031 B2	1/2010	Godfrey et al.
7,249,212 B2	7/2007	Do	7,672,714 B2	3/2010	Kuo
7,252,792 B2	8/2007	Perrault	7,673,679 B2	3/2010	Harrison et al.
7,253,716 B2	8/2007	Lovoi et al.	7,678,043 B2	3/2010	Gilad
7,261,690 B2	8/2007	Teller	7,686,839 B2	3/2010	Parker
7,270,633 B1	9/2007	Goscha	7,697,994 B2	4/2010	VanDanacker et al.
7,273,454 B2	9/2007	Raymond et al.	7,720,036 B2	5/2010	Sadri
7,289,855 B2	10/2007	Nghiem	7,729,776 B2	6/2010	Von Arx et al.
7,291,497 B2	11/2007	Holmes	7,733,224 B2	6/2010	Tran
7,292,139 B2	11/2007	Mazar et al.	7,736,318 B2	6/2010	Costentino
7,294,105 B1	11/2007	Islam	7,756,587 B2	7/2010	Penner et al.
7,311,665 B2	12/2007	Hawthorne	7,760,104 B2	7/2010	Asp
7,313,163 B2	12/2007	Liu	7,782,991 B2	8/2010	Sobchak et al.
7,317,378 B2	1/2008	Jarvis et al.	7,796,043 B2	9/2010	Euliano et al.
7,318,808 B2	1/2008	Tarassenko et al.	7,797,033 B2	9/2010	D'Andrea et al.
7,336,929 B2	2/2008	Yasuda	7,809,399 B2	10/2010	Lu
7,342,895 B2	3/2008	Serpa	7,844,341 B2	11/2010	Von Arx et al.
7,346,380 B2	3/2008	Axelgaard et al.	7,881,799 B2	2/2011	Greenberg et al.
7,349,722 B2	3/2008	Witkowski et al.	7,975,587 B2	7/2011	Schneider
7,352,998 B2	4/2008	Palin	7,978,064 B2	7/2011	Zdeblick et al.
7,353,258 B2	4/2008	Washburn	7,983,189 B2	7/2011	Bugenhagen
7,357,891 B2	4/2008	Yang et al.	8,036,731 B2	10/2011	Kimchy et al.
7,359,674 B2	4/2008	Markki	8,036,748 B2	10/2011	Zdeblick et al.
7,366,558 B2	4/2008	Virtanen et al.	8,054,047 B2	11/2011	Chen et al.
7,368,190 B2	5/2008	Heller et al.	8,054,140 B2	11/2011	Fleming et al.
7,368,191 B2	5/2008	Andelman et al.	8,055,334 B2	11/2011	Savage et al.
7,373,196 B2	5/2008	Ryu et al.	8,082,919 B2	12/2011	Brunnberg et al.
7,375,739 B2	5/2008	Robbins	8,119,045 B2	2/2012	Schmidt et al.
7,376,435 B2	5/2008	McGowan	8,131,376 B1	3/2012	Faraji et al.
7,382,247 B2	6/2008	Welch et al.	8,177,611 B2	5/2012	Kang
7,382,263 B2	6/2008	Danowski et al.	8,185,191 B1	5/2012	Shapiro et al.
7,387,607 B2	6/2008	Holt	8,185,646 B2	5/2012	Headley
7,388,903 B2	6/2008	Godfrey et al.	8,200,320 B2	6/2012	Kovacs
7,389,088 B2	6/2008	Kim	8,207,731 B2	6/2012	Moskalenko
7,392,015 B1	6/2008	Farlow	8,224,596 B2	7/2012	Agrawal et al.
7,395,106 B2	7/2008	Ryu et al.	8,253,586 B1	8/2012	Matak
7,396,330 B2	7/2008	Banet	8,254,853 B2	8/2012	Rofougaran
7,404,968 B2	7/2008	Abrams et al.	8,271,146 B2	9/2012	Heber et al.
7,413,544 B2	8/2008	Kerr	8,298,574 B2	10/2012	Tsabari et al.
7,414,534 B1	8/2008	Kroll et al.	8,343,068 B2	1/2013	Najafi et al.
7,414,543 B2	8/2008	Rye et al.	8,374,698 B2	2/2013	Ok et al.
7,415,242 B1	8/2008	Ngan	8,389,003 B2	3/2013	Mintchev et al.
7,424,268 B2	9/2008	Diener	8,404,275 B2	3/2013	Habboushe
7,424,319 B2	9/2008	Muehlsteff	8,425,492 B2	4/2013	Herbert et al.
7,427,266 B2	9/2008	Ayer et al.	8,443,214 B2	5/2013	Lee et al.
7,442,164 B2	10/2008	Berrang et al.	8,454,528 B2	6/2013	Yuen et al.
7,443,290 B2	10/2008	Takiguchi	8,532,776 B2	9/2013	Greenberg et al.
7,458,887 B2	12/2008	Kurosawa	8,540,664 B2	9/2013	Robertson et al.
7,469,838 B2	12/2008	Brooks et al.	8,545,402 B2	10/2013	Hafezi et al.
7,471,665 B2	12/2008	Perlman	8,547,248 B2	10/2013	Zdeblick et al.
7,471,992 B2	12/2008	Schmidt et al.	8,558,563 B2	10/2013	Zdeblick
7,492,128 B2	2/2009	Shen	8,564,432 B2	10/2013	Covannon et al.
7,499,674 B2	3/2009	Salokannel	8,597,186 B2	12/2013	Hafezi et al.
7,510,121 B2	3/2009	Koenck	8,634,838 B2	1/2014	Hellwig et al.
7,512,448 B2	3/2009	Malick	8,647,358 B2	2/2014	Brister et al.
7,515,043 B2	4/2009	Welch	8,660,645 B2	2/2014	Stevenson et al.
7,519,416 B2	4/2009	Sula et al.	8,668,643 B2	3/2014	Kinast
7,523,756 B2	4/2009	Minai	8,685,451 B2	4/2014	Toneguzzo et al.
			8,697,057 B2	4/2014	Van Epps et al.
			8,698,006 B2	4/2014	Bealka et al.
			8,758,237 B2	6/2014	Sherman et al.
			8,784,308 B2	7/2014	Duck et al.

(56)

## References Cited

## U.S. PATENT DOCUMENTS

8,802,183 B2	8/2014	Frank et al.	2003/0162556 A1	8/2003	Libes
8,816,847 B2	8/2014	Zdeblick et al.	2003/0164401 A1	9/2003	Andreasson et al.
8,836,513 B2	9/2014	Hafezi et al.	2003/0167000 A1	9/2003	Mullick et al.
8,838,217 B2	9/2014	Myr	2003/0171791 A1	9/2003	KenKnight
8,858,432 B2	10/2014	Robertson	2003/0171898 A1	9/2003	Tarassenko et al.
8,908,943 B2	12/2014	Berry et al.	2003/0181788 A1	9/2003	Yokoi et al.
8,912,908 B2	12/2014	Berkman et al.	2003/0185286 A1	10/2003	Yuen
8,926,509 B2	1/2015	Magar et al.	2003/0187337 A1	10/2003	Tarassenko et al.
8,932,221 B2	1/2015	Colliou et al.	2003/0187338 A1	10/2003	Say et al.
8,945,005 B2	2/2015	Hafezi et al.	2003/0195403 A1	10/2003	Berner et al.
8,951,234 B2	2/2015	Hafezi et al.	2003/0213495 A1	11/2003	Fujita et al.
8,989,837 B2	3/2015	Weinstein et al.	2003/0214579 A1	11/2003	Iddan
9,031,658 B2	5/2015	Chiao et al.	2003/0215563 A1 *	11/2003	Bunick ..... A61K 9/2866 427/2.1
9,088,168 B2	7/2015	Mach et al.	2003/0216622 A1	11/2003	Meron et al.
9,107,806 B2	8/2015	Hafezi et al.	2003/0216625 A1	11/2003	Phipps
9,119,554 B2	9/2015	Robertson et al.	2003/0216666 A1	11/2003	Ericson et al.
9,119,918 B2	9/2015	Robertson et al.	2003/0216729 A1	11/2003	Marchitto
9,149,423 B2	10/2015	Duck et al.	2003/0219484 A1	11/2003	Sowden et al.
9,158,890 B2	10/2015	Meredith et al.	2003/0232895 A1	12/2003	Omidian et al.
9,161,707 B2	10/2015	Hafezi et al.	2004/0008123 A1	1/2004	Carrender et al.
9,189,941 B2	11/2015	Eschelman et al.	2004/0018476 A1	1/2004	LaDue
9,226,663 B2	1/2016	Fei	2004/0034295 A1	2/2004	Salganicoff
9,226,679 B2	1/2016	Balda	2004/0049245 A1	3/2004	Gass
9,268,909 B2	2/2016	Jani et al.	2004/0073095 A1	4/2004	Causey et al.
9,270,025 B2	2/2016	Robertson et al.	2004/0073454 A1	4/2004	Urquhart et al.
9,271,897 B2	3/2016	Costello et al.	2004/0077995 A1	4/2004	Ferek-Petric
9,277,864 B2	3/2016	Yang et al.	2004/0082982 A1	4/2004	Gord et al.
9,320,455 B2	4/2016	Hafezi et al.	2004/0087839 A1	5/2004	Raymond et al.
9,415,010 B2	8/2016	Hafezi et al.	2004/0092801 A1	5/2004	Drakulic
9,433,371 B2	9/2016	Hafezi et al.	2004/0106859 A1	6/2004	Say et al.
9,439,582 B2	9/2016	Berkman et al.	2004/0115507 A1	6/2004	Potter et al.
9,439,599 B2	9/2016	Thompson et al.	2004/0115517 A1	6/2004	Fukada et al.
9,517,012 B2	12/2016	Lane et al.	2004/0117062 A1	6/2004	Bonney
9,597,010 B2	3/2017	Thompson et al.	2004/0121015 A1	6/2004	Chidlaw et al.
9,597,487 B2	3/2017	Robertson et al.	2004/0148140 A1	7/2004	Tarassenko et al.
9,599,679 B2	3/2017	Taylor et al.	2004/0153007 A1	8/2004	Harris
9,649,066 B2	5/2017	Zdeblick et al.	2004/0167226 A1	8/2004	Serafini
9,681,842 B2	6/2017	Zdeblick et al.	2004/0167465 A1	8/2004	Mihai et al.
9,741,975 B2	8/2017	Laulicht et al.	2004/0167801 A1	8/2004	Say et al.
9,756,874 B2	9/2017	Arne et al.	2004/0193020 A1	9/2004	Chiba
9,968,284 B2	5/2018	Vidalis et al.	2004/0193029 A1	9/2004	Gluhovsky
2001/0027331 A1	10/2001	Thompson	2004/0193446 A1	9/2004	Mayer et al.
2001/0044588 A1	11/2001	Mault	2004/0199222 A1	10/2004	Sun et al.
2001/0051766 A1	12/2001	Gazdinski	2004/0215084 A1	10/2004	Shimizu et al.
2002/0002326 A1	1/2002	Causey et al.	2004/0218683 A1	11/2004	Batra
2002/0026111 A1	2/2002	Ackerman	2004/0220643 A1	11/2004	Schmidt
2002/0032384 A1	3/2002	Raymond et al.	2004/0224644 A1	11/2004	Wu
2002/0032385 A1	3/2002	Raymond et al.	2004/0225199 A1	11/2004	Evanyk
2002/0040278 A1	4/2002	Anuzis et al.	2004/0253304 A1 *	12/2004	Gross ..... A61B 1/041 424/451
2002/0077620 A1	6/2002	Sweeney et al.	2004/0258571 A1	12/2004	Lee et al.
2002/0099423 A1	7/2002	Berg et al.	2004/0259899 A1 *	12/2004	Sanghvi ..... A61K 9/0031 514/282
2002/0128934 A1	9/2002	Shaer	2004/0260154 A1	12/2004	Sidelnik
2002/0132226 A1	9/2002	Nair	2005/0003074 A1	1/2005	Brown et al.
2002/0136744 A1	9/2002	McGlynn et al.	2005/0017841 A1	1/2005	Doi
2002/0179921 A1	12/2002	Cohn	2005/0020887 A1	1/2005	Goldberg
2002/0192159 A1	12/2002	Reitberg	2005/0021370 A1	1/2005	Riff
2002/0193669 A1	12/2002	Glukhovsky	2005/0024198 A1	2/2005	Ward
2002/0198470 A1	12/2002	Imran et al.	2005/0027205 A1	2/2005	Tarassenko et al.
2003/0017826 A1	1/2003	Fishman et al.	2005/0038321 A1	2/2005	Fujita et al.
2003/0023150 A1	1/2003	Yokoi et al.	2005/0043634 A1	2/2005	Yokoi et al.
2003/0028226 A1	2/2003	Thompson	2005/0043894 A1	2/2005	Fernandez
2003/0039956 A1 *	2/2003	Choi ..... A61K 9/1652 435/5	2005/0054897 A1	3/2005	Hashimoto et al.
2003/0062551 A1	4/2003	Chen et al.	2005/0055014 A1	3/2005	Coppeta et al.
2003/0065536 A1	4/2003	Hansen	2005/0062644 A1	3/2005	Leci
2003/0076179 A1	4/2003	Branch et al.	2005/0065407 A1	3/2005	Nakamura et al.
2003/0083559 A1	5/2003	Thompson	2005/0070778 A1	3/2005	Lackey
2003/0091625 A1	5/2003	Hariharan et al.	2005/0075145 A1	4/2005	Dvorak et al.
2003/0126593 A1	7/2003	Mault	2005/0090753 A1	4/2005	Goor et al.
2003/0130714 A1	7/2003	Nielsen et al.	2005/0092108 A1	5/2005	Andermo
2003/0135128 A1	7/2003	Suffin et al.	2005/0096514 A1	5/2005	Starkebaum
2003/0135392 A1	7/2003	Vrijens et al.	2005/0096562 A1	5/2005	Delalic et al.
2003/0152622 A1	8/2003	Louie-Helm et al.	2005/0101843 A1	5/2005	Quinn
2003/0158466 A1	8/2003	Lynn et al.	2005/0101872 A1	5/2005	Sattler
2003/0158756 A1	8/2003	Abramson	2005/0115561 A1	6/2005	Stahmann et al.
			2005/0116820 A1	6/2005	Goldreich
			2005/0117389 A1	6/2005	Worledge

(56)

## References Cited

## U.S. PATENT DOCUMENTS

2005/0121322 A1	6/2005	Say et al.	2007/0006636 A1	1/2007	King et al.
2005/0131281 A1	6/2005	Ayer et al.	2007/0008113 A1	1/2007	Spoonhower et al.
2005/0143623 A1	6/2005	Kojima	2007/0016089 A1	1/2007	Fischell et al.
2005/0146594 A1	7/2005	Nakatani et al.	2007/0027386 A1	2/2007	Such
2005/0148883 A1	7/2005	Boesen	2007/0027388 A1	2/2007	Chou
2005/0154428 A1	7/2005	Bruinsma	2007/0029195 A1	2/2007	Li et al.
2005/0156709 A1	7/2005	Gilbert et al.	2007/0038054 A1	2/2007	Zhou
2005/0165323 A1	7/2005	Montgomery	2007/0049339 A1	3/2007	Barak et al.
2005/0177069 A1	8/2005	Takizawa	2007/0055098 A1	3/2007	Shimizu et al.
2005/0182389 A1	8/2005	LaPorte	2007/0060797 A1	3/2007	Ball
2005/0187789 A1	8/2005	Hatlestad et al.	2007/0060800 A1	3/2007	Drinan et al.
2005/0192489 A1	9/2005	Marshall	2007/0066929 A1	3/2007	Ferren et al.
2005/0197680 A1	9/2005	DelMain et al.	2007/0073353 A1	3/2007	Rooney et al.
2005/0208251 A1	9/2005	Aisenbrey	2007/0096765 A1	5/2007	Kagan
2005/0228268 A1	10/2005	Cole	2007/0106346 A1	5/2007	Bergelson
2005/0234307 A1	10/2005	Heinonen	2007/0123772 A1	5/2007	Euliano
2005/0240305 A1	10/2005	Bogash et al.	2007/0129622 A1	6/2007	Bourget
2005/0245794 A1	11/2005	Dinsmoor	2007/0130287 A1	6/2007	Kumar
2005/0259768 A1	11/2005	Yang et al.	2007/0135803 A1	6/2007	Belson
2005/0261559 A1	11/2005	Mumford	2007/0142721 A1	6/2007	Berner et al.
2005/0267556 A1	12/2005	Shuros et al.	2007/0156016 A1	7/2007	Betesh
2005/0267756 A1	12/2005	Schultz et al.	2007/0160789 A1	7/2007	Merical
2005/0277912 A1	12/2005	John	2007/0162089 A1	7/2007	Mosesov
2005/0277999 A1	12/2005	Strother et al.	2007/0162090 A1	7/2007	Penner
2005/0279054 A1	12/2005	Mauze et al.	2007/0167495 A1	7/2007	Brown et al.
2005/0280539 A1	12/2005	Pettus	2007/0167848 A1	7/2007	Kuo et al.
2005/0285746 A1	12/2005	Sengupta	2007/0173701 A1	7/2007	Al-Ali
2005/0288594 A1	12/2005	Lewkowicz et al.	2007/0179347 A1	8/2007	Tarassenko et al.
2006/0001496 A1	1/2006	Abrosimov et al.	2007/0179371 A1	8/2007	Peyser et al.
2006/0028727 A1	2/2006	Moon et al.	2007/0185393 A1	8/2007	Zhou
2006/0036134 A1	2/2006	Tarassenko et al.	2007/0191002 A1	8/2007	Ge
2006/0058602 A1	3/2006	Kwiatkowski et al.	2007/0196456 A1	8/2007	Stevens
2006/0061472 A1	3/2006	Lovoi et al.	2007/0207793 A1	9/2007	Myer
2006/0065713 A1	3/2006	Kingery	2007/0208233 A1	9/2007	Kovacs
2006/0068006 A1	3/2006	Begleiter	2007/0213659 A1	9/2007	Trovato et al.
2006/0074283 A1	4/2006	Henderson	2007/0237719 A1	10/2007	Jones
2006/0074319 A1	4/2006	Barnes et al.	2007/0244370 A1	10/2007	Kuo et al.
2006/0078765 A1	4/2006	Yang et al.	2007/0255198 A1	11/2007	Leong et al.
2006/0095091 A1	5/2006	Drew	2007/0255330 A1	11/2007	Lee
2006/0095093 A1	5/2006	Betesh et al.	2007/0270672 A1	11/2007	Hayter
2006/0100533 A1	5/2006	Han	2007/0279217 A1	12/2007	Venkatraman
2006/0109058 A1	5/2006	Keating	2007/0282174 A1	12/2007	Sabatino
2006/0110962 A1	5/2006	Powell	2007/0282177 A1	12/2007	Pilz
2006/0122474 A1	6/2006	Teller et al.	2007/0299480 A1	12/2007	Hill
2006/0122494 A1	6/2006	Bouchoucha	2008/0000804 A1	1/2008	Carey et al.
2006/0122667 A1	6/2006	Chavan et al.	2008/0014866 A1	1/2008	Lipowshi
2006/0129060 A1	6/2006	Lee et al.	2008/0020037 A1	1/2008	Robertson et al.
2006/0136266 A1	6/2006	Tarassenko et al.	2008/0021519 A1	1/2008	DeGeest
2006/0142648 A1	6/2006	Banet	2008/0021521 A1	1/2008	Shah
2006/0145876 A1	7/2006	Kimura	2008/0027679 A1	1/2008	Shklarski
2006/0148254 A1	7/2006	McLean	2008/0033273 A1	2/2008	Zhou
2006/0149339 A1	7/2006	Burnes	2008/0038588 A1	2/2008	Lee
2006/0155174 A1	7/2006	Glukhovskiy et al.	2008/0039700 A1	2/2008	Drinan et al.
2006/0155183 A1	7/2006	Kroecker	2008/0045843 A1	2/2008	Tsuji et al.
2006/0161225 A1	7/2006	Sormann et al.	2008/0046038 A1	2/2008	Hill
2006/0179949 A1	8/2006	Kim	2008/0051647 A1	2/2008	Wu et al.
2006/0183993 A1	8/2006	Horn	2008/0051667 A1	2/2008	Goldreich
2006/0184092 A1	8/2006	Atanasoska et al.	2008/0058614 A1	3/2008	Banet
2006/0204738 A1	9/2006	Dubrow et al.	2008/0062856 A1	3/2008	Feher
2006/0210626 A1	9/2006	Spaeder	2008/0065168 A1	3/2008	Bitton et al.
2006/0216603 A1	9/2006	Choi	2008/0074307 A1	3/2008	Boric-Lubecke
2006/0218011 A1	9/2006	Walker	2008/0077015 A1	3/2008	Botic-Lubecke
2006/0235489 A1	10/2006	Drew	2008/0077028 A1	3/2008	Schaldach et al.
2006/0243288 A1	11/2006	Kim et al.	2008/0077188 A1	3/2008	Denker et al.
2006/0247505 A1	11/2006	Siddiqui	2008/0091089 A1	4/2008	Guillory et al.
2006/0253005 A1	11/2006	Drinan	2008/0091114 A1	4/2008	Min
2006/0270346 A1	11/2006	Ibrahim	2008/0097549 A1	4/2008	Colbaugh
2006/0273882 A1	12/2006	Posamentier	2008/0097917 A1	4/2008	Dicks
2006/0276702 A1	12/2006	McGinnis	2008/0103440 A1	5/2008	Ferren et al.
2006/0280227 A1	12/2006	Pinkney	2008/0112885 A1	5/2008	Okunev et al.
2006/0282001 A1	12/2006	Noel	2008/0114224 A1	5/2008	Bandy et al.
2006/0289640 A1	12/2006	Mercure	2008/0119705 A1	5/2008	Patel
2006/0293607 A1	12/2006	Alt	2008/0119716 A1	5/2008	Boric-Lubecke
2007/0000776 A1	1/2007	Karube et al.	2008/0121825 A1	5/2008	Trovato et al.
2007/0002038 A1	1/2007	Suzuki	2008/0137566 A1	6/2008	Marholev
			2008/0139907 A1	6/2008	Rao et al.
			2008/0140403 A1	6/2008	Hughes et al.
			2008/0146871 A1	6/2008	Arneson et al.
			2008/0146889 A1	6/2008	Young

(56)

## References Cited

## U.S. PATENT DOCUMENTS

2008/0146892 A1	6/2008	LeBeouf	2009/0177060 A1	7/2009	Say et al.
2008/0154104 A1	6/2008	Lamego	2009/0177061 A1	7/2009	Say et al.
2008/0166992 A1	7/2008	Ricordi	2009/0177062 A1	7/2009	Say et al.
2008/0175898 A1	7/2008	Jones et al.	2009/0177063 A1	7/2009	Say et al.
2008/0183245 A1	7/2008	Van Oort	2009/0177064 A1	7/2009	Say et al.
2008/0188837 A1	8/2008	Belsky et al.	2009/0177065 A1	7/2009	Say et al.
2008/0194912 A1	8/2008	Trovato et al.	2009/0177066 A1	7/2009	Say et al.
2008/0208009 A1	8/2008	Shklarski	2009/0182206 A1	7/2009	Najafi
2008/0214901 A1	9/2008	Gehman	2009/0182207 A1	7/2009	Riskey et al.
2008/0214985 A1	9/2008	Yanaki	2009/0182212 A1	7/2009	Say et al.
2008/0243020 A1	10/2008	Chou	2009/0182213 A1	7/2009	Say et al.
2008/0249360 A1	10/2008	Li	2009/0182214 A1	7/2009	Say et al.
2008/0262320 A1	10/2008	Schaefer et al.	2009/0182215 A1	7/2009	Say et al.
2008/0262336 A1	10/2008	Ryu	2009/0182388 A1	7/2009	Von Arx
2008/0269664 A1	10/2008	Trovato et al.	2009/0187088 A1	7/2009	Say et al.
2008/0275312 A1	11/2008	Mosesov	2009/0187089 A1	7/2009	Say et al.
2008/0284599 A1 *	11/2008	Zdeblick et al. .... A61B 5/0031 340/572.1	2009/0187090 A1	7/2009	Say et al.
2008/0288027 A1	11/2008	Kroll	2009/0187091 A1	7/2009	Say et al.
2008/0294020 A1	11/2008	Sapounas	2009/0187092 A1	7/2009	Say et al.
2008/0299197 A1	12/2008	Toneguzzo et al.	2009/0187093 A1	7/2009	Say et al.
2008/0300572 A1	12/2008	Rankers	2009/0187094 A1	7/2009	Say et al.
2008/0303638 A1	12/2008	Nguyen	2009/0187095 A1	7/2009	Say et al.
2008/0306357 A1	12/2008	Korman	2009/0187381 A1	7/2009	King et al.
2008/0306359 A1	12/2008	Zdeblick et al.	2009/0192351 A1	7/2009	Nishino
2008/0306360 A1	12/2008	Robertson et al.	2009/0192368 A1	7/2009	Say et al.
2008/0311852 A1	12/2008	Hansen	2009/0192369 A1	7/2009	Say et al.
2008/0312522 A1	12/2008	Rowlandson	2009/0192370 A1	7/2009	Say et al.
2008/0316020 A1	12/2008	Robertson	2009/0192371 A1	7/2009	Say et al.
2009/0009330 A1	1/2009	Sakama et al.	2009/0192372 A1	7/2009	Say et al.
2009/0009332 A1	1/2009	Nunez et al.	2009/0192373 A1	7/2009	Say et al.
2009/0024045 A1	1/2009	Prakash	2009/0192374 A1	7/2009	Say et al.
2009/0024112 A1	1/2009	Edwards et al.	2009/0192375 A1	7/2009	Say et al.
2009/0030293 A1	1/2009	Cooper et al.	2009/0192376 A1	7/2009	Say et al.
2009/0030297 A1	1/2009	Miller	2009/0192377 A1	7/2009	Say et al.
2009/0034209 A1	2/2009	Joo	2009/0192378 A1	7/2009	Say et al.
2009/0043171 A1	2/2009	Rule	2009/0192379 A1	7/2009	Say et al.
2009/0047357 A1	2/2009	Tomohira et al.	2009/0194747 A1	8/2009	Zou et al.
2009/0048498 A1	2/2009	Riskey	2009/0197068 A1	8/2009	Yamaguchi et al.
2009/0062634 A1	3/2009	Say et al.	2009/0198115 A1	8/2009	Say et al.
2009/0062670 A1	3/2009	Sterling	2009/0198116 A1	8/2009	Say et al.
2009/0062730 A1	3/2009	Woo	2009/0198175 A1	8/2009	Say et al.
2009/0069642 A1	3/2009	Gao	2009/0203964 A1	8/2009	Shimizu et al.
2009/0069655 A1	3/2009	Say et al.	2009/0203971 A1	8/2009	Sciarappa
2009/0069656 A1	3/2009	Say et al.	2009/0203972 A1	8/2009	Heneghan
2009/0069657 A1	3/2009	Say et al.	2009/0203978 A1	8/2009	Say et al.
2009/0069658 A1	3/2009	Say et al.	2009/0204265 A1	8/2009	Hackett
2009/0069724 A1	3/2009	Otto et al.	2009/0210164 A1	8/2009	Say et al.
2009/0076343 A1	3/2009	James	2009/0216101 A1	8/2009	Say et al.
2009/0076350 A1	3/2009	Bly et al.	2009/0216102 A1	8/2009	Say et al.
2009/0082645 A1	3/2009	Hafezi et al.	2009/0227204 A1	9/2009	Robertson et al.
2009/0087483 A1	4/2009	Sison	2009/0227876 A1	9/2009	Tran
2009/0088618 A1	4/2009	Ameson	2009/0227940 A1	9/2009	Say et al.
2009/0099435 A1	4/2009	Say et al.	2009/0227941 A1	9/2009	Say et al.
2009/0105561 A1	4/2009	Boydon et al.	2009/0227988 A1	9/2009	Wood et al.
2009/0110148 A1	4/2009	Zhang	2009/0228214 A1	9/2009	Say et al.
2009/0112626 A1	4/2009	Talbot	2009/0231125 A1	9/2009	Baldus
2009/0124871 A1	5/2009	Arshak	2009/0234200 A1	9/2009	Husheer
2009/0124965 A1	5/2009	Greenberg et al.	2009/0243833 A1	10/2009	Huang
2009/0131774 A1	5/2009	Sweitzer	2009/0253960 A1	10/2009	Takenaka et al.
2009/0135886 A1	5/2009	Robertson et al.	2009/0256702 A1	10/2009	Robertson
2009/0142853 A1	6/2009	Warrington et al.	2009/0260212 A1	10/2009	Schmett et al.
2009/0149839 A1	6/2009	Hyde et al.	2009/0264714 A1	10/2009	Chou
2009/0157113 A1	6/2009	Marcotte	2009/0264964 A1	10/2009	Abrahamson
2009/0157358 A1	6/2009	Kim	2009/0265186 A1	10/2009	Tarassenko et al.
2009/0161602 A1	6/2009	Matsumoto	2009/0273467 A1	11/2009	Elixmann
2009/0163789 A1	6/2009	Say et al.	2009/0281539 A1	11/2009	Selig
2009/0171180 A1	7/2009	Pering	2009/0287109 A1	11/2009	Ferren et al.
2009/0171420 A1	7/2009	Brown et al.	2009/0295548 A1	12/2009	Ronkka
2009/0173628 A1	7/2009	Say et al.	2009/0296677 A1	12/2009	Mahany
2009/0177055 A1	7/2009	Say et al.	2009/0303920 A1	12/2009	Mahany
2009/0177056 A1	7/2009	Say et al.	2009/0306633 A1	12/2009	Trovato et al.
2009/0177057 A1	7/2009	Say et al.	2009/0312619 A1	12/2009	Say et al.
2009/0177058 A1	7/2009	Say et al.	2009/0318303 A1	12/2009	Delamarche et al.
2009/0177059 A1	7/2009	Say et al.	2009/0318761 A1	12/2009	Rabinovitz
			2009/0318779 A1	12/2009	Tran
			2009/0318783 A1	12/2009	Rohde
			2009/0318793 A1	12/2009	Datta
			2010/0001841 A1	1/2010	Cardullo
			2010/0010330 A1	1/2010	Rankers

(56)

## References Cited

## U.S. PATENT DOCUMENTS

2010/0033324	A1	2/2010	Shimizu et al.	
2010/0036269	A1	2/2010	Ferren et al.	
2010/0049004	A1	2/2010	Edman et al.	
2010/0049006	A1	2/2010	Magar	
2010/0049012	A1	2/2010	Dijksman et al.	
2010/0049069	A1	2/2010	Tarassenko et al.	
2010/0056878	A1	3/2010	Partin	
2010/0056891	A1	3/2010	Say et al.	
2010/0056939	A1	3/2010	Tarassenko et al.	
2010/0057041	A1	3/2010	Hayter	
2010/0062709	A1	3/2010	Kato	
2010/0063438	A1	3/2010	Bengtsson	
2010/0063841	A1	3/2010	D'Ambrosia et al.	
2010/0069002	A1	3/2010	Rong	
2010/0069717	A1	3/2010	Hafezi et al.	
2010/0099967	A1	4/2010	Say et al.	
2010/0099968	A1	4/2010	Say et al.	
2010/0099969	A1	4/2010	Say et al.	
2010/0100077	A1	4/2010	Rush	
2010/0100078	A1	4/2010	Say et al.	
2010/0106001	A1	4/2010	Say et al.	
2010/0118853	A1	5/2010	Godfrey	
2010/0139672	A1	6/2010	Kroll et al.	
2010/0168659	A1	7/2010	Say et al.	
2010/0179398	A1	7/2010	Say et al.	
2010/0191073	A1	7/2010	Tarassenko et al.	
2010/0210299	A1	8/2010	Gorbachov	
2010/0222652	A1	9/2010	Cho	
2010/0228113	A1	9/2010	Solosko	
2010/0233026	A1	9/2010	Ismagliov et al.	
2010/0234706	A1	9/2010	Gilland	
2010/0234715	A1	9/2010	Shin	
2010/0234914	A1	9/2010	Shen	
2010/0239616	A1*	9/2010	Hafezi .....	A61B 5/073 424/400
2010/0245091	A1	9/2010	Singh	
2010/0249541	A1	9/2010	Geva et al.	
2010/0249881	A1	9/2010	Corndorf	
2010/0256461	A1	10/2010	Mohamedali	
2010/0259543	A1	10/2010	Tarassenko et al.	
2010/0268048	A1	10/2010	Say et al.	
2010/0268049	A1	10/2010	Say et al.	
2010/0268050	A1	10/2010	Say et al.	
2010/0274111	A1	10/2010	Say et al.	
2010/0280345	A1	11/2010	Say et al.	
2010/0280346	A1	11/2010	Say et al.	
2010/0295694	A1	11/2010	Kauffman et al.	
2010/0297640	A1	11/2010	Kumar et al.	
2010/0298650	A1	11/2010	Moon et al.	
2010/0298668	A1	11/2010	Hafezi et al.	
2010/0298730	A1	11/2010	Tarassenko et al.	
2010/0312188	A1	12/2010	Robertson et al.	
2010/0312580	A1	12/2010	Tarassenko et al.	
2011/0009715	A1	1/2011	O'Reilly et al.	
2011/0065983	A1	3/2011	Hafezi et al.	
2011/0077660	A1	3/2011	Janik et al.	
2011/0124983	A1	5/2011	Kroll et al.	
2011/0134906	A1	6/2011	Garudadri et al.	
2011/0160549	A1	6/2011	Saroka et al.	
2011/0224912	A1	9/2011	Bhavaraju et al.	
2011/0230732	A1	9/2011	Edman et al.	
2011/0270135	A1	11/2011	Dooley et al.	
2012/0004520	A1	1/2012	Whitworth et al.	
2012/0011699	A1	1/2012	Hafezi et al.	
2012/0016231	A1	1/2012	Westmoreland	
2012/0032816	A1	2/2012	Cho et al.	
2012/0062371	A1	3/2012	Radivojevic et al.	
2012/0071743	A1	3/2012	Todorov et al.	
2012/0109112	A1	5/2012	Strand et al.	
2012/0179004	A1	7/2012	Roesicke et al.	
2012/0245043	A1	9/2012	England	
2012/0276451	A1	11/2012	Lestriez et al.	
2012/0299723	A1	11/2012	Hafezi et al.	
2013/0129869	A1	5/2013	Hafezi et al.	
2013/0129872	A1	5/2013	Kruger	

2013/0131283	A1	5/2013	Wang et al.
2013/0171596	A1	7/2013	French
2013/0172690	A1	7/2013	Arne et al.
2013/0185228	A1	7/2013	Dresner
2013/0196012	A1	8/2013	Dill
2013/0199662	A1	8/2013	Gebbink
2013/0209877	A1	8/2013	Kren et al.
2013/0223028	A1	8/2013	Arne et al.
2013/0275296	A1	10/2013	Tietzen et al.
2014/0066734	A1	3/2014	Zdeblick
2014/0179221	A1	6/2014	Whitworth et al.
2014/0180202	A1	6/2014	Zdeblick et al.
2014/0280125	A1	9/2014	Bhardwaj et al.
2014/0308930	A1	10/2014	Tran
2014/0349256	A1	11/2014	Connor
2014/0374276	A1	12/2014	Guthrie et al.
2015/0017486	A1	1/2015	Lai
2015/0059922	A1	3/2015	Thompson et al.
2015/0080678	A1	3/2015	Frank et al.
2015/0080679	A1	3/2015	Frank et al.
2015/0080680	A1	3/2015	Zdeblick et al.
2015/0112243	A1	4/2015	Hafezi et al.
2015/0127737	A1	5/2015	Thompson et al.
2015/0127738	A1	5/2015	Thompson et al.
2015/0149375	A1	5/2015	Thompson et al.
2015/0150480	A1	6/2015	Zdeblick et al.
2015/0164746	A1	6/2015	Costello et al.
2015/0230729	A1	8/2015	Zdeblick et al.
2015/0248833	A1	9/2015	Arne et al.
2015/0352343	A1	12/2015	Hafezi et al.
2015/0361234	A1	12/2015	Hafezi et al.
2016/0033667	A1	2/2016	Schmidt et al.
2016/0345906	A1	12/2016	Johnson et al.
2016/0380708	A1	12/2016	Dua et al.
2017/0000179	A1	1/2017	Cheng et al.
2017/0014046	A1	1/2017	Hafezi et al.
2017/0020182	A1	1/2017	Schmidt et al.
2017/0216569	A1	8/2017	Hafezi et al.
2017/0265813	A1	9/2017	Zdeblick et al.
2017/0274194	A1	9/2017	Robertson et al.
2017/0296799	A1	10/2017	Hafezi et al.
2018/0026680	A1	1/2018	Shirvani et al.
2018/0110441	A1	4/2018	Frank et al.
2018/0184698	A1	7/2018	Arne et al.
2018/0214048	A1	8/2018	Zdeblick et al.
2018/0229996	A1	8/2018	Thompson

## FOREIGN PATENT DOCUMENTS

CN	101795202	8/2010
DE	10313005	10/2004
EP	0344939	12/1989
EP	0526166	2/1993
EP	0981152	2/2000
EP	1246356	10/2002
EP	1534054	5/2005
EP	1702553	9/2006
EP	1244308	12/2007
EP	2143369	1/2010
GB	827762	2/1960
JP	61072712	4/1986
JP	H01285247	11/1989
JP	05228128	9/1993
JP	H11195415	7/1999
JP	2000506410	5/2000
JP	2002263185	9/2002
JP	2002282219	10/2002
JP	2003050867	2/2003
JP	2004313242	11/2004
JP	2005073886	3/2005
JP	2005087552	4/2005
JP	2005102959	4/2005
JP	2005124708	5/2005
JP	2005514966	5/2005
JP	2005304880	11/2005
JP	2005343515	12/2005
JP	20055332328	12/2005
JP	2006006377	1/2006
JP	2006509574	3/2006



## (56) References Cited

## FOREIGN PATENT DOCUMENTS

JP	2007200739	8/2007
JP	2007313340	12/2007
JP	2009514870	4/2009
JP	2009528909	8/2009
KR	200600977523	7/2006
TW	200406192	5/2004
TW	200916136	4/2009
WO	WO1988002237	4/1988
WO	WO1992021307	12/1992
WO	WO1993008734	5/1993
WO	WO1993019667	10/1993
WO	WO1994001165	1/1994
WO	WO1997039963	10/1997
WO	WO1998043537	10/1998
WO	WO1999037290	7/1999
WO	WO1999059465	11/1999
WO	WO2000032474	6/2000
WO	WO2000033246	6/2000
WO	WO2001000085	1/2001
WO	WO2001047466	7/2001
WO	WO2001058236	8/2001
WO	WO2001074011	10/2001
WO	WO2001080731	11/2001
WO	WO2002000920	1/2002
WO	WO2002045489	6/2002
WO	WO2002058330	7/2002
WO	WO2002062276	8/2002
WO	WO2002087681	11/2002
WO	WO2002095351	11/2002
WO	WO2003005877	1/2003
WO	WO2003050643	6/2003
WO	WO2003068061	8/2003
WO	WO2004014225	2/2004
WO	WO2004019172	3/2004
WO	WO2004039256	5/2004
WO	WO2004066833	8/2004
WO	WO2004066834	8/2004
WO	WO2004066903	8/2004
WO	WO2004068881	8/2004
WO	WO2004075032	9/2004
WO	WO2004109316	12/2004
WO	WO2005011237	2/2005
WO	WO2005020023	3/2005
WO	WO2005024687	3/2005
WO	WO2005041438	5/2005
WO	WO2005047837	5/2005
WO	WO2005051166	6/2005
WO	WO2005053517	6/2005
WO	WO2005083621	9/2005
WO	WO2005110238	11/2005
WO	WO2005123569	12/2005
WO	WO2006021932	3/2006
WO	WO2006027586	3/2006
WO	WO2006028347	3/2006
WO	WO2006055892	5/2006
WO	WO2006055956	5/2006
WO	WO2006075016	7/2006
WO	WO2006100620	9/2006
WO	WO2006104843	10/2006
WO	WO2006116718	11/2006
WO	WO-2006116718 A2 *	11/2006
WO	WO2006127355	11/2006
WO	WO2007001724	1/2007
WO	WO2007001742	1/2007
WO	WO2007013952	2/2007
WO	WO2007014084	2/2007
WO	WO2007014527	2/2007
WO	WO2007021496	2/2007
WO	WO2007027660	3/2007
WO	WO2007028035	3/2007
WO	WO2007036687	4/2007
WO	WO2007036741	4/2007
WO	WO2007036746	4/2007
WO	WO2007040878	4/2007
WO	WO2007067054	6/2007

WO	WO2007071180	6/2007
WO	WO2007096810	8/2007
WO	WO2007101141	9/2007
WO	WO2007115087	10/2007
WO	WO2007120946	10/2007
WO	WO2007127316	11/2007
WO	WO2007127879	11/2007
WO	WO2007128165	11/2007
WO	WO2007130491	11/2007
WO	WO2007143535	12/2007
WO	WO2007149546	12/2007
WO	WO2008008281	1/2008
WO	WO2008012700	1/2008
WO	WO2008030482	3/2008
WO	WO2008052136	5/2008
WO	WO-2008052136 A2 *	5/2008
WO	WO2008063626	5/2008
WO	WO2008066617	6/2008
WO	WO2008076464	6/2008
WO	WO2008089232	7/2008
WO	WO2008091683	7/2008
WO	WO2008095183	8/2008
WO	WO2008097652	8/2008
WO	WO2008101107	8/2008
WO	WO2008112577	9/2008
WO	WO2008112578	9/2008
WO	WO2008120156	10/2008
WO	WO2008133394	11/2008
WO	WO2008134185	11/2008
WO	WO2008150633	12/2008
WO	WO2009000447	12/2008
WO	WO2009001108	12/2008
WO	WO2009006615	1/2009
WO	WO2009029453	3/2009
WO	WO2009031149	3/2009
WO	WO2009036334	3/2009
WO	WO2009051829	4/2009
WO	WO2009051830	4/2009
WO	WO2009063377	5/2009
WO	WO2009081348	7/2009
WO	WO2009111664	9/2009
WO	WO2009146082	12/2009
WO	WO2010009100	1/2010
WO	WO2010011833	1/2010
WO	WO2010019778	2/2010
WO	WO2010057049	5/2010
WO	WO2010080765	7/2010
WO	WO2010080843	7/2010
WO	WO2010107563	9/2010
WO	WO2010129288	11/2010
WO	WO2010132331	11/2010
WO	WO2010135516	11/2010
WO	WO2011068963	6/2011
WO	WO2011133799	10/2011
WO	WO2011159336	12/2011
WO	WO2011159337	12/2011
WO	WO2011159338	12/2011
WO	WO2011159339	12/2011
WO	WO2012112561	8/2012
WO	WO2015112603	7/2015
WO	WO2015112604	7/2015
WO	WO2015119911	8/2015

## OTHER PUBLICATIONS

Arshak et al., A Review and Adaptation of Methods of Object Tracking to Telemetry Capsules IC-Med (2007) vol. 1, No. 1, Issue 1, 12pp.

"ASGE Technology Status Evaluation Report: wireless capsule endoscopy" American Soc. for Gastrointestinal Endoscopy (2006) vol. 63, No. 4; 7 pp.

Au-Yeung, K., et al., "A Networked System for Self-Management of Drug Therapy and Wellness", Wireless Health '10, Oct. 5-7, 2010, San Diego, 9 pp.

Aydin et al., "Design and implementation considerations for an advanced wireless interface in miniaturized integrated sensor Microsystems" Sch. of Eng. & Electron., Edinburgh Univ., UK; (2003); abstract (1 page).

(56)

## References Cited

## OTHER PUBLICATIONS

- Barrie, Heidelberg pH capsule gastric analysis. Textbook of Natural Medicine, (1992), Pizzorno, Murray & Barrie (4 pages).
- Bohidar et al., "Dielectric Behavior of Gelatin Solutions and Gels" Colloid Polym Sci (1998) 276:81-86.
- Brock, "Smart Medicine: The Application of Auto-ID Technology to Healthcare" Auto-ID Labs (2002) <http://www.autoidlabs.org/uploads/media/MIT-AUTOID-WH-010.pdf> (14 pages).
- Carlson et al., "Evaluation of a non-invasive respiratory monitoring system for sleeping subjects" Physiological Measurement (1999) 20(1): 53.
- Courty, L. "Conductance Measurement Part 1: Theory"; Current Separations, 18:3 (1999) p. 91-96.
- Delvaux et al., "Capsule endoscopy: Technique and indications" Clinical Gastroenterology (2008) vol. 22, Issue 5, pp. 813-837.
- Description of ePatch Technology Platform for ECG and EMG, located at [http://www.madebydelta.com/imported/images/DELTA\\_Web/documents/ME/ePatch\\_ECG\\_EMG.pdf](http://www.madebydelta.com/imported/images/DELTA_Web/documents/ME/ePatch_ECG_EMG.pdf), Dated Sep. 2, 2010; 1 page.
- Dhar et al., "Electroless nickel plated contacts on porous silicon" Appl. Phys. Lett. 68 (10) pp. 1392-1393 (1996).
- Eldek A., "Design of double dipole antenna with enhanced usable bandwidth for wideband phased array applications" Progress in Electromagnetics Research PIER 59, 1-15 (2006).
- Fawaz et al., "Enhanced Telemetry System using CP-QPSK Band—Pass Modulation Technique Suitable for Smart Pill Medical Application" IFIP IEEE Dubai Conference (2008); [http://www.asic.fh-offenburg.de/downloads/ePille/IFIP\\_IEEE\\_Dubai\\_Conference.pdf](http://www.asic.fh-offenburg.de/downloads/ePille/IFIP_IEEE_Dubai_Conference.pdf) (5 pages).
- Ferguson et al., "Dielectric Constant Studies III Aqueous Gelatin Solutions" J. Chem. Phys. 2, 94 (1934) p. 94-98.
- Furse C. M., "Dipole Antennas" J. Webster (ed). Wiley Encyclopedia of Electrical and Electronics Engineering (1999) p. 575-581.
- Gagliani S. "Put Your Phone, or Skin, on Vibrate" MedGadget (2012) <http://medgadget.com/2012/03/put-your-phone-or-skin-on-vibrate.html> 8pp.
- Gilson, D.R. "Molecular dynamics simulation of dipole interactions", Department of Physics, Hull University, Dec. (2002), p. 1-43.
- Given Imaging, "Agile Patency Brochure" (2006) [http://www.inclino.no/documents/AgilePatencyBrochure\\_Global\\_GMB-0118-01.pdf](http://www.inclino.no/documents/AgilePatencyBrochure_Global_GMB-0118-01.pdf); 4pp.
- Gonzalez-Guillaumin et al., "Ingestible capsule for impedance and pH monitoring in the esophagus" IEEE Trans Biomed Eng. (2007) 54(12): 2231-6; abstract.
- Greene, "Edible RFID microchip monitor can tell if you take your medicine" Bloomberg Businessweek (2010) 2 pp.; <http://www.businessweek.com/idg/2010-03-31/edible-rfid-microchip-monitor-can-tell-if-you-take-your-medicine.html> (1 page).
- Heydari et al., "Analysis of the PLL jitter due to power/ground and substrate noise"; IEEE Transactions on Circuits and Systems (2004) 51(12): 2404-16.
- Hoeksma, J. "New 'smart pill' to track adherence" E-Health-Insider (2010) [http://www.e-health-insider.com/news/5910/new\\_'smart\\_pill'\\_monitors\\_medicines](http://www.e-health-insider.com/news/5910/new_'smart_pill'_monitors_medicines) (1 page).
- Hoover et al., "Rx for health: Engineers design pill that signals it has been swallowed" University of Florida News (2010) 2pp.; <http://news.ufl.edu/2010/03/31/antenna-pill-2/>.
- Intramedic, MicroCam Innovative Capsule Endoscope Pamphlet. (2006) 8 pp (<http://www.intramedic.com/en/product/productinfo.asp>) (8 pages).
- ISFET—Ion Sensitive Field-Effect Transistor; Microsens S.A. pdf document. First cited by Examiner in Office Action dated Jun. 13 (2011) for U.S. Appl. No. 12/238,345; 4pp.
- Jung, S. "Dissolvable 'Transient Electronics' Will Be Good for Your Body and the Environment" MedGadget; Oct. 1 (2012); Online website: <http://medgadget.com/2012/10/dissolvable-transient-electronics-will-be-good-for-your-body-and-the-environment.html>; downloaded Oct. 24, 2012; 4 pp.
- Juvenile Diabetes Research Foundation International (JDRF), "Artificial Pancreas Project" (2010); <http://www.artificialpancreasproject.com/>; 3 pp.
- Kamada K., "Electrophoretic deposition assisted by soluble anode" Materials Letters 57 (2003) 2348-2351.
- Kendle, Earl R. and Morris, Larry A., "Preliminary Studies in the Development of a Gastric Battery for Fish" (1964). Nebraska Game and Parks Commission White Papers, Conference Presentations, & Manuscripts. Paper 22. p. 1-6.
- Kim et al., "A Semi-Interpenetrating Network System for a Polymer Membrane"; Eur. Polym. J. vol. 33 No. 7; pp. 1009-1014 (1997).
- Li, P-Y, et al. "An electrochemical intraocular drug delivery device", Sensors and Actuators A 143 (2008) p. 41-48.
- Lifescan, "OneTouch UltraLink™" <http://www.lifescan.com/products/meters/ultralink> (2010) 2 pp.
- Mackay et al., "Radio Telemetry from within the Body" Inside Information is Revealed by Tiny Transmitters that can be Swallowed or Implanted in Man or Animal Science (1991) 1196-1202; 134; American Association for the Advancement of Science, Washington D.C.
- Mackay et al., "Endoradiosonde" Nature, (1957) 1239-1240, 179 Nature Publishing Group.
- McKenzie et al., "Validation of a new telemetric core temperature monitor" J. Therm. Biol. (2004) 29(7-8):605-11.
- Medtronic, "CareLink Therapy Management Software for Diabetes" (2010); <https://carelink.minimed.com/patient/entry.jsp?bhcp=1>; 1 pp.
- Medtronic, "Carelink™ USB" (2008) [http://www.medtronicdiabetes.com/pdf/carelink\\_usb\\_factsheet.pdf](http://www.medtronicdiabetes.com/pdf/carelink_usb_factsheet.pdf) 2pp.
- Medtronic "The New MiniMed Paradigm® REAL-Time Revel™ System" (2010) <http://www.medtronicdiabetes.com/products/index.html>; 2 pp.
- Medtronic, "MINI MED Paradigm® Revel™ Insulin Pump" (2010) <http://www.medtronicdiabetes.com/products/insulinpumps/index.html>; 2 pp.
- Medtronic, Mini Med Paradigm™ Veo™ System: Factsheet (2010). <http://www.medtronic-diabetes.com.au/downloads/Paradigm%20Veo%20Factsheet.pdf>; 4 pp.
- Melanson, "Walkers swallow RFID pills for science" Engadget (2008); <http://www.engadget.com/2008/07/29/walkers-swallow-rfid-pills-for-science/> (1 page).
- Minimitter Co. Inc. "Actiheart" Traditional 510(k) Summary. Sep. 27, (2005) (8 pages).
- Minimitter Co. Inc. Noninvasive technology to help your studies succeed. Mini Mitter.com Mar. 31, (2009) (4 pages).
- Mini Mitter Co, Inc. 510(k) Premarket Notification Mini-Logger for Diagnostic Spirometer. 9-21 (1999) (9 pages).
- Mini Mitter Co, Inc. 510(k) Premarket Notification for VitalSense. Apr. 22, 2004 (11 pages).
- Minimitter Co. Inc. VitalSense Integrated Physiological Monitoring System. Product Description. (2005) (4 pages).
- Minimitter Co. Inc. VitalSense Wireless Vital Signs Monitoring. Temperatures.com Mar. 31, 2009 (3 pages).
- Mojaverian et al., "Estimation of gastric residence time of the Heidelberg capsule in humans: effect of varying food composition" Gastroenterology (1985) 89(2): 392-7.
- O'Brien et al., "The Production and Characterization of Chemically Reactive Porous Coatings of Zirconium Via Unbalanced Magnetron Sputtering" Surface and Coatings Technology (1996) 86-87; 200-206.
- Park, "Medtronic to Buy MiniMed for \$3.7 Billion" (2001) HomeCare; [http://homecaremag.com/mag/medical\\_medtronic\\_buy\\_minimed/](http://homecaremag.com/mag/medical_medtronic_buy_minimed/); 2 pp.
- Philips Respironics Products, Noninvasive Technology to Help Your Studies Succeed. 510 (k) Permanent Notification for Vital Sense. Apr. 22, 2004; <http://minimitter.com/products.cfm>.
- Radio Antennae, <http://www.erikdeman.de/html/sail018h.htm>; (2008) 5 pages.
- "RFID 'pill' monitors marchers" RFID News (2008) <http://www.rfidnews.org/2008/07/23/rfid-pill-monitors-marchers/> (4 pages).
- Rolison et al., "Electrically conductive oxide aerogels: new materials in electrochemistry" J. Mater. Chem. (2001) 1, 963-980.


(56)

## References Cited


## OTHER PUBLICATIONS

- Roulstone, et al., "Studies on Polymer Latex Films: I. A study of latex film morphology" *Polymer International* 24 (1991) pp. 87-94.
- Sanduleanu et al., "Octave tunable, highly linear, RC-ring oscillator with differential fine-coarse tuning, quadrature outputs and amplitude control for fiber optic transceivers" (2002) *IEEE MTT-S International Microwave Symposium Digest* 545-8.
- Santini, J.T. et al., "Microchips as controlled drug delivery-devices", *Angew. Chem. Int. Ed.* (2000), vol. 39, p. 2396-2407.
- "SensiVida minimally invasive clinical systems" Investor Presentation Oct. (2009) 28pp; <http://www.sensividamedtech.com/SensiVidaGeneralOctober09.pdf>; pp. 1-28.
- Shawgo, R.S. et al. "BioMEMS from drug delivery", *Current Opinion in Solid State and Material Science* 6 (2002), p. 329-334.
- Shin et al., "A Simple Route to Metal Nanodots and Nanoporous Metal Films"; *Nano Letters*, vol. 2, No. 9 (2002) pp. 933-936.
- Shrivastava et al., "A New Platform for Bioelectronics-Electronic Pill", *Cummins College*, (2010); [http://www.cumminscollege.org/downloads/electronics\\_and\\_telecommunication/Newsletters/Current%20Newsletters.pdf](http://www.cumminscollege.org/downloads/electronics_and_telecommunication/Newsletters/Current%20Newsletters.pdf); First cited in third party client search conducted by Patent Eagle Search May 18, 2010 (2010); pp. 11-12.
- "Smartlife awarded patent for knitted transducer" *Innovation in Textiles News*: <http://www.innovationintextiles.com/articles/208.php>; 2pp. (2009).
- "The SmartPill Wireless Motility Capsule" SMARTPILL, The Measure of GI Health; (2010) [http://www.smartpillcorp.com/index.cfm?pagepath=Products/The\\_SmartPill\\_Capsule&id=17814](http://www.smartpillcorp.com/index.cfm?pagepath=Products/The_SmartPill_Capsule&id=17814) (1 page).
- Solanas et al., "RFID Technology for the Health Care Sector" *Recent Patents on Electrical Engineering* (2008) 1, 22-31.
- Soper, S.A. et al. "Bio-Mems Technologies and Applications", Chapter 12, "MEMS for Drug Delivery", p. 325-346 (2007).
- Swedberg, "University Team Sees Ingestible RFID Tag as a Boon to Clinical Trials" *RFID Journal* (2010) Apr. 27; <http://www.rfidjournal.com/article/view/7560/1> 3pp.
- Tajalli et al., "Improving the power-delay performance in subthreshold source-coupled logic circuits" *Integrated Circuit and System Design. Power and Timing Modeling, Optimization and Simulation*, Springer Berlin Heidelberg (2008) 21-30.
- Target Innovations, Tablet Metal Detector, <http://web.archive.org/web/20130215063351/http://www.metaldetectorindia.com/tablet-metal-detector.html>, Feb. 15, 2013.
- TargetPharmaceutical Metal Detector, Feb. 15, 2013 downloaded from Target Innovations, Tablet Metal Detector, Feb. 15, 2013.
- Tatbul et al., "Confidence-based data management for personal area sensor networks" *ACM International Conference Proceeding Series* (2004) 72; 3 pages.
- Tierney, M.J. et al. "Electroreleasing Composite Membranes for Delivery of Insulin and other Biomacromolecules", *J. Electrochem. Soc.*, vol. 137, No. 6, Jun. (1990), p. 2005-2006.
- Trutag Technologies, Inc., Spectral Microtags for Authentication and Anti-Counterfeiting; "Product Authentication and Brand Protection Solutions"; <http://www.trutags.com/>; downloaded Feb. 12, 2013; 1 pp.
- Walkey, "MOSFET Structure and Processing"; 97.398\* *Physical Electronics Lecture* 20; 24 pp.
- Wang, X. et al. "Resistance to Tracking and Erosion of Silicone Rubber Material under Various Types of Precipitation", *Jpn. J. Appl. Phys.* vol. 38 (1999) pp. 5170-5175.
- Watson, et al., "Determination of the relationship between the pH and conductivity of gastric juice" *Physiol Meas.* 17 (1996) pp. 21-27.
- Winter, J. et al. "The material properties of gelatin gels"; *USA Ballistic Research Laboratories*, Mar. (1975), p. 1-157.
- Wongmanerod et al., "Determination of pore size distribution and surface area of thin porous silicon layers by spectroscopic ellipsometry" *Applied Surface Science* 172 (2001) 117-125.
- Xiaoming et al., "A telemedicine system for wireless home healthcare based on bluetooth and the internet" *Telemedicine Journal and e-health* (2004) 10(S2): S110-6.
- Yang et al., "Fast-switching frequency synthesizer with a discriminator-aided phase detector" *IEEE Journal of Solid-State Circuits* (2000) 35(10): 1445-52.
- Yao et al., "Low Power Digital Communication in Implantable Devices Using vol. Conduction of Biological Tissues" *Proceedings of the 28th IEEE, EMBS Annual International Conference*, Aug. 30-Sep. 3, (2006); pp. 6249-6252.
- Youtube video Pharmaceutical Metal Detector/Tablet Metal Detector/ Capsule Metal Detector/ Dry Fruits; [https://www.youtube.com/watch?v=I0126txam\\_s](https://www.youtube.com/watch?v=I0126txam_s), May 12, 2012.
- Zimmerman, "Personal Area Networks: Near-field intrabody communication" *IBM Systems Journal* (1996) 35 (3-4):609-17.
- Zworkin, "A Radio Pill" *Nature*, (1957) 898, 179 Nature Publishing Group.


\* cited by examiner



**FIG. 1**



**FIG. 2A**



**FIG. 2B**

FIG.3




FIG.4





FIG.5




FIG.5A




FIG. 5B




FIG. 6

# COMMUNICATION SYSTEM WITH PARTIAL POWER SOURCE

## CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation application claiming priority under 35 U.S.C. § 120 to U.S. patent application Ser. No. 14/865,508, filed Sep. 25, 2015, now U.S. Pat. No. 9,649,066, which is a continuation application claiming priority under 35 U.S.C. § 120 to U.S. patent application Ser. No. 14/341,639, filed Jul. 25, 2014, now U.S. Patent Application Publication No. 2015/0080680 which is a continuation application claiming priority under 35 U.S.C. § 120 to U.S. patent application Ser. No. 13/153,312, filed Jun. 3, 2011, now U.S. Pat. No. 8,816,847, which is a continuation application claiming priority under 35 U.S.C. § 120 to U.S. patent application Ser. No. 12/564,017, filed Sep. 21, 2009, now U.S. Pat. No. 7,978,064, the entire disclosures of which are hereby herein incorporated by reference herein.

## FIELD

The present invention is related to systems for detection of an event. More specifically, the present disclosure includes a system that includes a partial power source that can be activated when in contact with conductive liquid and is capable of controlling conductance to mark an event.

## BACKGROUND

Ingestible devices that include electronic circuitry have been proposed for use in a variety of different medical applications, including both diagnostic and therapeutic applications. These devices typically require an internal power supply for operation. Examples of such ingestible devices are ingestible electronic capsules which collect data as they pass through the body, and transmit the data to an external receiver system. An example of this type of electronic capsule is an in-vivo video camera. The swallowable capsule includes a camera system and an optical system for imaging an area of interest onto the camera system. The transmitter transmits the video output of the camera system and the reception system receives the transmitted video output. Other examples include an ingestible imaging device, which has an internal and self contained power source, which obtains images from within body lumens or cavities. The electronic circuit components of the device are enclosed by an inert indigestible housing (e.g. glass housing) that passes through the body internally. Other examples include an ingestible data recorder capsule medical device. The electronic circuits of the disclosed device (e.g. sensor, recorder, battery etc.) are housed in a capsule made of inert materials.

In other examples, fragile radio frequency identification (RFID) tags are used in drug ingestion monitoring applications. In order for the RFID tags to be operational, each requires an internal power supply. The RFID tags are antenna structures that are configured to transmit a radio-frequency signal through the body.

The problem these existing devices pose is that the power source is internal to device and such power sources are costly to produce and potentially harmful to the surrounding environment if the power source leaks or is damaged. Additionally, having antennas extending from the device is a concern as related to the antennas getting damaged or causing a problem when the device is used in-vivo. There-

fore, what is needed is suitable system with circuitry that eliminates the need for an internal power source and antennas.

## SUMMARY

The present disclosure includes a system for producing a unique signature that indicates the occurrence of an event. The system includes circuitry and components that can be placed within certain environments that include a conducting fluid. One example of such an environment is inside a container that houses the conducting fluid, such as a sealed bag with a solution, which includes an IV bag. Another example is within the body of a living organism, such as an animal or a human. The systems are ingestible and/or digestible or partially digestible. The system includes dissimilar materials positioned on the framework such that when a conducting fluid comes into contact with the dissimilar materials, a voltage potential difference is created. The voltage potential difference, and hence the voltage, is used to power up control logic that is positioned within the framework. Ions or current flows from the first dissimilar material to the second dissimilar material via the control logic and then through the conducting fluid to complete a circuit. The control logic controls the conductance between the two dissimilar materials and, hence, controls or modulates the conductance.

As the ingestible circuitry is made up of ingestible, and even digestible, components, the ingestible circuitry results in little, if any, unwanted side effects, even when employed in chronic situations. Examples of the range of components that may be included are: logic and/or memory elements; effectors; a signal transmission element; and a passive element, such as a resistor or inductor. The one or more components on the surface of the support may be laid out in any convenient configuration. Where two or more components are present on the surface of the solid support, interconnects may be provided. All of the components and the support of the ingestible circuitry are ingestible, and in certain instances digestible or partially digestible.

## BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows a pharmaceutical product with an event indicator system according to the teaching of the present invention, wherein the product and the event indicator system combination are within the body.

FIG. 2A shows the pharmaceutical product of FIG. 1 with the event indicator system on the exterior of the pharmaceutical product.

FIG. 2B shows the pharmaceutical product of FIG. 1 with the event indicator system positioned inside the pharmaceutical product.

FIG. 3 is a block diagram representation of one aspect of the event indicator system with dissimilar metals positioned on opposite ends.

FIG. 4 is a block diagram representation of another aspect of the event indicator system with dissimilar metals positioned on the same end and separated by a non-conducting material.

FIG. 5 shows ionic transfer or the current path through a conducting fluid when the event indicator system of FIG. 3 is in contact with conducting liquid and in an active state.

FIG. 5A shows an exploded view of the surface of dissimilar materials of FIG. 5.

FIG. 5B shows the event indicator system of FIG. 5 with a pH sensor unit.

FIG. 6 is a block diagram illustration of one aspect of the control device used in the system of FIGS. 3 and 4.

#### DETAILED DESCRIPTION

The present disclosure includes multiple embodiments for indicating the occurrence of an event. As described in more detail below, a system of the present invention is used with a conducting fluid to indicate the event marked by contact between the conducting fluid and the system. For example, the system of the present disclosure may be used with pharmaceutical product and the event that is indicated is when the product is taken or ingested. The term “ingested” or “ingest” or “ingesting” is understood to mean any introduction of the system internal to the body. For example, ingesting includes simply placing the system in the mouth all the way to the descending colon. Thus, the term ingesting refers to any instant in time when the system is introduced to an environment that contains a conducting fluid. Another example would be a situation when a non-conducting fluid is mixed with a conducting fluid. In such a situation the system would be present in the non-conduction fluid and when the two fluids are mixed, the system comes into contact with the conducting fluid and the system is activated. Yet another example would be the situation when the presence of certain conducting fluids needed to be detected. In such instances, the presence of the system, which would be activated, within the conducting fluid could be detected and, hence, the presence of the respective fluid would be detected.

Referring again to the instance where the system is used with the product that is ingested by the living organism, when the product that includes the system is taken or ingested, the device comes into contact with the conducting liquid of the body. When the system of the present invention comes into contact with the body fluid, a voltage potential is created and the system is activated. A portion of the power source is provided by the device, while another portion of the power source is provided by the conducting fluid, which is discussed in detail below.

Referring now to FIG. 1, an ingestible product 14 that includes a system of the present invention is shown inside the body. The product 14 is configured as an orally ingestible pharmaceutical formulation in the form of a pill or capsule. Upon ingestion, the pill moves to the stomach. Upon reaching the stomach, the product 14 is in contact with stomach fluid 18 and undergoes a chemical reaction with the various materials in the stomach fluid 18, such as hydrochloric acid and other digestive agents. The system of the present invention is discussed in reference to a pharmaceutical environment. However, the scope of the present invention is not limited thereby. The present invention can be used in any environment where a conducting fluid is present or becomes present through mixing of two or more components that result in a conducting liquid.

Referring now to FIG. 2A, a pharmaceutical product 10, similar to the product 14 of FIG. 1, is shown with a system 12, such as an ingestible event marker or an ionic emission module. The scope of the present invention is not limited by the shape or type of the product 10. For example, it will be clear to one skilled in the art that the product 10 can be a capsule, a time-release oral dosage, a tablet, a gel cap, a sub-lingual tablet, or any oral dosage product that can be combined with the system 12. In the referenced embodiment, the product 10 has the system 12 secured to the exterior using known methods of securing micro-devices to the exterior of pharmaceutical products. Example of meth-

ods for securing the micro-device to the product is disclosed in U.S. Provisional Application No. 61/142,849 filed on Jan. 1, 2009 and entitled “HIGH-THROUGHPUT PRODUCTION OF INGESTIBLE EVENT MARKERS” as well as U.S. Provisional Application No. 61/177,611 filed on May 12, 2009 and entitled “INGESTIBLE EVENT MARKERS COMPRISING AN IDENTIFIER AND AN INGESTIBLE COMPONENT”, the entire disclosure of each is incorporated herein by reference. Once ingested, the system 12 comes into contact with body liquids and the system 12 is activated. The system 12 uses the voltage potential difference to power up and thereafter modulates conductance to create a unique and identifiable current signature. Upon activation, the system 12 controls the conductance and, hence, current flow to produce the current signature.

There are various reasons for delaying the activation of the system 12. In order to delay the activation of the system 12, the system 12 may be coated with a shielding material or protective layer. The layer is dissolved over a period of time, thereby allowing the system 12 to be activated when the product 10 has reached a target location.

Referring now to FIG. 2B, a pharmaceutical product 20, similar to the product 14 of FIG. 1, is shown with a system 22, such as an ingestible event marker or an identifiable emission module. The scope of the present invention is not limited by the environment to which the system 22 is introduced. For example, the system 22 can be enclosed in a capsule that is taken in addition to/independently from the pharmaceutical product. The capsule may be simply a carrier for the system 22 and may not contain any product. Furthermore, the scope of the present invention is not limited by the shape or type of product 20. For example, it will be clear to one skilled in the art that the product 20 can be a capsule, a time-release oral dosage, a tablet, a gel capsule, a sub-lingual tablet, or any oral dosage product. In the referenced embodiment, the product 20 has the system 22 positioned inside or secured to the interior of the product 20. In one embodiment, the system 22 is secured to the interior wall of the product 20. When the system 22 is positioned inside a gel capsule, then the content of the gel capsule is a non-conducting gel-liquid. On the other hand, if the content of the gel capsule is a conducting gel-liquid, then in an alternative embodiment, the system 22 is coated with a protective cover to prevent unwanted activation by the gel capsule content. If the content of the capsule is a dry powder or microspheres, then the system 22 is positioned or placed within the capsule. If the product 20 is a tablet or hard pill, then the system 22 is held in place inside the tablet. Once ingested, the product 20 containing the system 22 is dissolved. The system 22 comes into contact with body liquids and the system 22 is activated. Depending on the product 20, the system 22 may be positioned in either a near-central or near-perimeter position depending on the desired activation delay between the time of initial ingestion and activation of the system 22. For example, a central position for the system 22 means that it will take longer for the system 22 to be in contact with the conducting liquid and, hence, it will take longer for the system 22 to be activated. Therefore, it will take longer for the occurrence of the event to be detected.

Referring now to FIG. 3, in one embodiment, the systems 12 and 22 of FIGS. 2A and 2B, respectively, are shown in more detail as system 30. The system 30 can be used in association with any pharmaceutical product, as mentioned above, to determine when a patient takes the pharmaceutical product. As indicated above, the scope of the present invention is not limited by the environment and the product that is used with the system 30. For example, the system 30 may



be placed within a capsule and the capsule is placed within the conducting liquid. The capsule would then dissolve over a period of time and release the system 30 into the conducting liquid. Thus, in one embodiment, the capsule would contain the system 30 and no product. Such a capsule may then be used in any environment where a conducting liquid is present and with any product. For example, the capsule may be dropped into a container filled with jet fuel, salt water, tomato sauce, motor oil, or any similar product. Additionally, the capsule containing the system 30 may be ingested at the same time that any pharmaceutical product is ingested in order to record the occurrence of the event, such as when the product was taken.

In the specific example of the system 30 combined with the pharmaceutical product, as the product or pill is ingested, the system 30 is activated. The system 30 controls conductance to produce a unique current signature that is detected, thereby signifying that the pharmaceutical product has been taken. The system 30 includes a framework 32. The framework 32 is a chassis for the system 30 and multiple components are attached to, deposited upon, or secured to the framework 32. In this embodiment of the system 30, a digestible material 34 is physically associated with the framework 32. The material 34 may be chemically deposited on, evaporated onto, secured to, or built-up on the framework all of which may be referred to herein as "deposit" with respect to the framework 32. The material 34 is deposited on one side of the framework 32. The materials of interest that can be used as material 34 include, but are not limited to: Cu or CuI. The material 34 is deposited by physical vapor deposition, electrodeposition, or plasma deposition, among other protocols. The material 34 may be from about 0.05 to about 500  $\mu\text{m}$  thick, such as from about 5 to about 100  $\mu\text{m}$  thick. The shape is controlled by shadow mask deposition, or photolithography and etching. Additionally, even though only one region is shown for depositing the material, each system 30 may contain two or more electrically unique regions where the material 34 may be deposited, as desired.

At a different side, which is the opposite side as shown in FIG. 3, another digestible material 36 is deposited, such that materials 34 and 36 are dissimilar. Although not shown, the different side selected may be the side next to the side selected for the material 34. The scope of the present invention is not limited by the side selected and the term "different side" can mean any of the multiple sides that are different from the first selected side. Furthermore, even though the shape of the system is shown as a square, the shape may be any geometrically suitable shape. Material 34 and 36 are selected such that they produce a voltage potential difference when the system 30 is in contact with conducting liquid, such as body fluids. The materials of interest for material 36 include, but are not limited to: Mg, Zn, or other electronegative metals. As indicated above with respect to the material 34, the material 36 may be chemically deposited on, evaporated onto, secured to, or built-up on the framework. Also, an adhesion layer may be necessary to help the material 36 (as well as material 34 when needed) to adhere to the framework 32. Typical adhesion layers for the material 36 are Ti, TiW, Cr or similar material. Anode material and the adhesion layer may be deposited by physical vapor deposition, electrodeposition or plasma deposition. The material 36 may be from about 0.05 to about 500  $\mu\text{m}$  thick, such as from about 5 to about 100  $\mu\text{m}$  thick. However, the scope of the present invention is not limited by

the thickness of any of the materials nor by the type of process used to deposit or secure the materials to the framework 32.

According to the disclosure set forth, the materials 34 and 36 can be any pair of materials with different electrochemical potentials. Additionally, in the embodiments wherein the system 30 is used in-vivo, the materials 34 and 36 may be vitamins that can be absorbed. More specifically, the materials 34 and 36 can be made of any two materials appropriate for the environment in which the system 30 will be operating. For example, when used with an ingestible product, the materials 34 and 36 are any pair of materials with different electrochemical potentials that are ingestible. An illustrative example includes the instance when the system 30 is in contact with an ionic solution, such as stomach acids. Suitable materials are not restricted to metals, and in certain embodiments the paired materials are chosen from metals and non-metals, e.g., a pair made up of a metal (such as Mg) and a salt (such as CuCl or CuI). With respect to the active electrode materials, any pairing of substances—metals, salts, or intercalation compounds—with suitably different electrochemical potentials (voltage) and low interfacial resistance are suitable.

Materials and pairings of interest include, but are not limited to, those reported in Table 1 below. In one embodiment, one or both of the metals may be doped with a non-metal, e.g., to enhance the voltage potential created between the materials as they come into contact with a conducting liquid. Non-metals that may be used as doping agents in certain embodiments include, but are not limited to: sulfur, iodine and the like. In another embodiment, the materials are copper iodine (CuI) as the anode and magnesium (Mg) as the cathode. Embodiments of the present invention use electrode materials that are not harmful to the human body.

TABLE 1

	Anode	Cathode
Metals	Magnesium, Zinc Sodium (†), Lithium (†) Iron	
Salts		Copper salts: iodide, chloride, bromide, sulfate, formate, (other anions possible) Fe <sup>3+</sup> salts: e.g. orthophosphate, pyrophosphate, (other anions possible) Oxygen (††) on platinum, gold or other catalytic surfaces
Intercalation compounds	Graphite with Li, K, Ca, Na, Mg	Vanadium oxide Manganese oxide

Thus, when the system 30 is in contact with the conducting liquid, a current path, an example is shown in FIG. 5, is formed through the conducting liquid between material 34 and 36. A control device 38 is secured to the framework 32 and electrically coupled to the materials 34 and 36. The control device 38 includes electronic circuitry, for example control logic that is capable of controlling and altering the conductance between the materials 34 and 36.

The voltage potential created between the materials 34 and 36 provides the power for operating the system as well as produces the current flow through the conducting fluid and the system. In one embodiment, the system operates in direct current mode. In an alternative embodiment, the system controls the direction of the current so that the direction of current is reversed in a cyclic manner, similar to alternating current. As the system reaches the conducting fluid or the electrolyte, where the fluid or electrolyte com-

ponent is provided by a physiological fluid, e.g., stomach acid, the path for current flow between the materials **34** and **36** is completed external to the system **30**; the current path through the system **30** is controlled by the control device **38**. Completion of the current path allows for the current to flow and in turn a receiver, not shown, can detect the presence of the current and recognize that the system **30** has been activate and the desired event is occurring or has occurred.

In one embodiment, the two materials **34** and **36** are similar in function to the two electrodes needed for a direct current power source, such as a battery. The conducting liquid acts as the electrolyte needed to complete the power source. The completed power source described is defined by the physical chemical reaction between the materials **34** and **36** of the system **30** and the surrounding fluids of the body. The completed power source may be viewed as a power source that exploits reverse electrolysis in an ionic or a conduction solution such as gastric fluid, blood, or other bodily fluids and some tissues. Additionally, the environment may be something other than a body and the liquid may be any conducting liquid. For example, the conducting fluid may be salt water or a metallic based paint.

In certain embodiments, these two materials are shielded from the surrounding environment by an additional layer of material. Accordingly, when the shield is dissolved and the two dissimilar materials are exposed to the target site, a voltage potential is generated.

In certain embodiments, the complete power source or supply is one that is made up of active electrode materials, electrolytes, and inactive materials, such as current collectors, packaging, etc. The active materials are any pair of materials with different electrochemical potentials. Suitable materials are not restricted to metals, and in certain embodiments the paired materials are chosen from metals and non-metals, e.g., a pair made up of a metal (such as Mg) and a salt (such as CuI). With respect to the active electrode materials, any pairing of substances—metals, salts, or intercalation compounds—with suitably different electrochemical potentials (voltage) and low interfacial resistance are suitable.

A variety of different materials may be employed as the materials that form the electrodes. In certain embodiments, electrode materials are chosen to provide for a voltage upon contact with the target physiological site, e.g., the stomach, sufficient to drive the system of the identifier. In certain embodiments, the voltage provided by the electrode materials upon contact of the metals of the power source with the target physiological site is 0.001 V or higher, including 0.01 V or higher, such as 0.1 V or higher, e.g., 0.3 V or higher, including 0.5 volts or higher, and including 1.0 volts or higher, where in certain embodiments, the voltage ranges from about 0.001 to about 10 volts, such as from about 0.01 to about 10 V.

Referring again to FIG. 3, the materials **34** and **36** provide the voltage potential to activate the control device **38**. Once the control device **38** is activated or powered up, the control device **38** can alter conductance between the materials **34** and **36** in a unique manner. By altering the conductance between materials **34** and **36**, the control device **38** is capable of controlling the magnitude of the current through the conducting liquid that surrounds the system **30**. This produces a unique current signature that can be detected and measured by a receiver (not shown), which can be positioned internal or external to the body. In addition to controlling the magnitude of the current path between the materials, non-conducting materials, membrane, or “skirt” are used to increase the “length” of the current path and,

hence, act to boost the conductance path, as disclosed in the U.S. patent application Ser. No. 12/238,345 entitled, “In-Body Device with Virtual Dipole Signal Amplification” filed Sep. 25, 2008, the entire content of which is incorporated herein by reference. Alternatively, throughout the disclosure herein, the terms “non-conducting material”, “membrane”, and “skirt” are interchangeably with the term “current path extender” without impacting the scope or the present embodiments and the claims herein. The skirt, shown in portion at **35** and **37**, respectively, may be associated with, e.g., secured to, the framework **32**. Various shapes and configurations for the skirt are contemplated as within the scope of the present invention. For example, the system **30** may be surrounded entirely or partially by the skirt and the skirt maybe positioned along a central axis of the system **30** or off-center relative to a central axis. Thus, the scope of the present invention as claimed herein is not limited by the shape or size of the skirt. Furthermore, in other embodiments, the materials **34** and **36** may be separated by one skirt that is positioned in any defined region between the materials **34** and **36**.

Referring now to FIG. 4, in another embodiment, the systems **12** and **22** of FIGS. 2A and 2B, respectively, are shown in more detail as system **40**. The system **40** includes a framework **42**. The framework **42** is similar to the framework **32** of FIG. 3. In this embodiment of the system **40**, a digestible or dissolvable material **44** is deposited on a portion of one side of the framework **42**. At a different portion of the same side of the framework **42**, another digestible material **46** is deposited, such that materials **44** and **46** are dissimilar. More specifically, material **44** and **46** are selected such that they form a voltage potential difference when in contact with a conducting liquid, such as body fluids. Thus, when the system **40** is in contact with and/or partially in contact with the conducting liquid, then a current path, an example is shown in FIG. 5, is formed through the conducting liquid between material **44** and **46**. A control device **48** is secured to the framework **42** and electrically coupled to the materials **44** and **46**. The control device **48** includes electronic circuitry that is capable of controlling part of the conductance path between the materials **44** and **46**. The materials **44** and **46** are separated by a non-conducting skirt **49**. Various examples of the skirt **49** are disclosed in U.S. Provisional Application No. 61/173,511 filed on Apr. 28, 2009 and entitled “HIGHLY RELIABLE INGESTIBLE EVENT MARKERS AND METHODS OF USING SAME” and U.S. Provisional Application No. 61/173,564 filed on Apr. 28, 2009 and entitled “INGESTIBLE EVENT MARKERS HAVING SIGNAL AMPLIFIERS THAT COMPRISE AN ACTIVE AGENT”; as well as U.S. application Ser. No. 12/238,345 filed Sep. 25, 2008 and entitled “IN-BODY DEVICE WITH VIRTUAL DIPOLE SIGNAL AMPLIFICATION”; the entire disclosure of each is incorporated herein by reference.

Once the control device **48** is activated or powered up, the control device **48** can alter conductance between the materials **44** and **46**. Thus, the control device **48** is capable of controlling the magnitude of the current through the conducting liquid that surrounds the system **40**. As indicated above with respect to system **30**, a unique current signature that is associated with the system **40** can be detected by a receiver (not shown) to mark the activation of the system **40**. In order to increase the “length” of the current path the size of the skirt **49** is altered. The longer the current path, the easier it may be for the receiver to detect the current.

Referring now to FIG. 5, the system **30** of FIG. 3 is shown in an activated state and in contact with conducting liquid.

The system 30 is grounded through ground contact 52. The system 30 also includes a sensor module 74, which is described in greater detail with respect to FIG. 6. Ion or current paths 50 between material 34 to material 36 and through the conducting fluid in contact with the system 30. The voltage potential created between the material 34 and 36 is created through chemical reactions between materials 34/36 and the conducting fluid. FIG. 5A shows an exploded view of the surface of the material 34. The surface of the material 34 is not planar, but rather an irregular surface. The irregular surface increases the surface area of the material and, hence, the area that comes in contact with the conducting fluid.

In one embodiment, at the surface of the material 34, there is chemical reaction between the material 34 and the surrounding conducting fluid such that mass is released into the conducting fluid. The term "mass" as used herein refers to protons and neutrons that form a substance. One example includes the instant where the material is CuCl and when in contact with the conducting fluid, CuCl becomes Cu (solid) and Cl<sup>-</sup> in solution. The flow of ions into the conduction fluid is depicted by the ion paths 50. In a similar manner, there is a chemical reaction between the material 36 and the surrounding conducting fluid and ions are captured by the material 36. The release of ions at the material 34 and capture of ion by the material 36 is collectively referred to as the ionic exchange. The rate of ionic exchange and, hence the ionic emission rate or flow, is controlled by the control device 38. The control device 38 can increase or decrease the rate of ion flow by altering the conductance, which alters the impedance, between the materials 34 and 36. Through controlling the ion exchange, the system 30 can encode information in the ionic exchange process. Thus, the system 30 uses ionic emission to encode information in the ionic exchange.

The control device 38 can vary the duration of a fixed ionic exchange rate or current flow magnitude while keeping the rate or magnitude near constant, similar to when the frequency is modulated and the amplitude is constant. Also, the control device 38 can vary the level of the ionic exchange rate or the magnitude of the current flow while keeping the duration near constant. Thus, using various combinations of changes in duration and altering the rate or magnitude, the control device 38 encodes information in the current flow or the ionic exchange. For example, the control device 38 may use, but is not limited to any of the following techniques namely, Binary Phase-Shift Keying (PSK), Frequency modulation, Amplitude modulation, on-off keying, and PSK with on-off keying.

As indicated above, the various embodiments disclosed herein, such as systems 30 and 40 of FIGS. 3 and 4, respectively, include electronic components as part of the control device 38 or the control device 48. Components that may be present include but are not limited to: logic and/or memory elements, an integrated circuit, an inductor, a resistor, and sensors for measuring various parameters. Each component may be secured to the framework and/or to another component. The components on the surface of the support may be laid out in any convenient configuration. Where two or more components are present on the surface of the solid support, interconnects may be provided.

As indicated above, the system, such as system 30 and 40, control the conductance between the dissimilar materials and, hence, the rate of ionic exchange or the current flow. Through altering the conductance in a specific manner the system is capable of encoding information in the ionic exchange and the current signature. The ionic exchange or

the current signature is used to uniquely identify the specific system. Additionally, the systems 30 and 40 are capable of producing various different unique exchanges or signatures and, thus, provide additional information. For example, a second current signature based on a second conductance alteration pattern may be used to provide additional information, which information may be related to the physical environment. To further illustrate, a first current signature may be a very low current state that maintains an oscillator on the chip and a second current signature may be a current state at least a factor of ten higher than the current state associated with the first current signature.

Referring now to FIG. 6, a block diagram representation of the control device 38 is shown. The device 30 includes a control module 62, a counter or clock 64, and a memory 66. Additionally, the device 38 is shown to include a sensor module 72 as well as the sensor module 74, which was referenced in FIG. 5. The control module 62 has an input 68 electrically coupled to the material 34 and an output 70 electrically coupled to the material 36. The control module 62, the clock 64, the memory 66, and the sensor modules 72/74 also have power inputs (some not shown). The power for each of these components is supplied by the voltage potential produced by the chemical reaction between materials 34 and 36 and the conducting fluid, when the system 30 is in contact with the conducting fluid. The control module 62 controls the conductance through logic that alters the overall impedance of the system 30. The control module 62 is electrically coupled to the clock 64. The clock 64 provides a clock cycle to the control module 62. Based upon the programmed characteristics of the control module 62, when a set number of clock cycles have passed, the control module 62 alters the conductance characteristics between materials 34 and 36. This cycle is repeated and thereby the control device 38 produces a unique current signature characteristic. The control module 62 is also electrically coupled to the memory 66. Both the clock 64 and the memory 66 are powered by the voltage potential created between the materials 34 and 36.

The control module 62 is also electrically coupled to and in communication with the sensor modules 72 and 74. In the embodiment shown, the sensor module 72 is part of the control device 38 and the sensor module 74 is a separate component. In alternative embodiments, either one of the sensor modules 72 and 74 can be used without the other and the scope of the present invention is not limited by the structural or functional location of the sensor modules 72 or 74. Additionally, any component of the system 30 may be functionally or structurally moved, combined, or repositioned without limiting the scope of the present invention as claimed. Thus, it is possible to have one single structure, for example a processor, which is designed to perform the functions of all of the following modules: the control module 62, the clock 64, the memory 66, and the sensor module 72 or 74. On the other hand, it is also within the scope of the present invention to have each of these functional components located in independent structures that are linked electrically and able to communicate.

Referring again to FIG. 6, the sensor modules 72 or 74 can include any of the following sensors: temperature, pressure, pH level, and conductivity. In one embodiment, the sensor modules 72 or 74 gather information from the environment and communicate the analog information to the control module 62. The control module then converts the analog information to digital information and the digital information is encoded in the current flow or the rate of the transfer of mass that produces the ionic flow. In another embodiment,

the sensor modules 72 or 74 gather information from the environment and convert the analog information to digital information and then communicate the digital information to control module 62. In the embodiment shown in FIG. 5, the sensor modules 74 is shown as being electrically coupled to the material 34 and 36 as well as the control device 38. In another embodiment, as shown in FIG. 6, the sensor module 74 is electrically coupled to the control device 38 at connection 78. The connection 78 acts as both a source for power supply to the sensor module 74 and a communication channel between the sensor module 74 and the control device 38.

Referring now to FIG. 5B, the system 30 includes a pH sensor module 76 connected to a material 39, which is selected in accordance with the specific type of sensing function being performed. The pH sensor module 76 is also connected to the control device 38. The material 39 is electrically isolated from the material 34 by a non-conductive barrier 55. In one embodiment, the material 39 is platinum. In operation, the pH sensor module 76 uses the voltage potential difference between the materials 34/36. The pH sensor module 76 measures the voltage potential difference between the material 34 and the material 39 and records that value for later comparison. The pH sensor module 76 also measures the voltage potential difference between the material 39 and the material 36 and records that value for later comparison. The pH sensor module 76 calculates the pH level of the surrounding environment using the voltage potential values. The pH sensor module 76 provides that information to the control device 38. The control device 38 varies the rate of the transfer of mass that produces the ionic transfer and the current flow to encode the information relevant to the pH level in the ionic transfer, which can be detected by a receiver (not shown). Thus, the system 30 can determine and provide the information related to the pH level to a source external to the environment.

As indicated above, the control device 38 can be programmed in advance to output a pre-defined current signature. In another embodiment, the system can include a receiver system that can receive programming information when the system is activated. In another embodiment, not shown, the switch 64 and the memory 66 can be combined into one device.

In addition to the above components, the system 30 may also include one or other electronic components. Electrical components of interest include, but are not limited to: additional logic and/or memory elements, e.g., in the form of an integrated circuit; a power regulation device, e.g., battery, fuel cell or capacitor; a sensor, a stimulator, etc.; a signal transmission element, e.g., in the form of an antenna, electrode, coil, etc.; a passive element, e.g., an inductor, resistor, etc.

In certain embodiments, the ingestible circuitry includes a coating layer. The purpose of this coating layer can vary, e.g., to protect the circuitry, the chip and/or the battery, or any components during processing, during storage, or even during ingestion. In such instances, a coating on top of the circuitry may be included. Also of interest are coatings that are designed to protect the ingestible circuitry during storage, but dissolve immediately during use. For example, coatings that dissolve upon contact with an aqueous fluid, e.g. stomach fluid, or the conducting fluid as referenced above. Also of interest are protective processing coatings that are employed to allow the use of processing steps that would otherwise damage certain components of the device. For example, in embodiments where a chip with dissimilar material deposited on the top and bottom is produced, the

product needs to be diced. However, the dicing process can scratch off the dissimilar material, and also there might be liquid involved which would cause the dissimilar materials to discharge or dissolve. In such instances, a protective coating on the materials prevents mechanical or liquid contact with the component during processing can be employed. Another purpose of the dissolvable coatings may be to delay activation of the device. For example, the coating that sits on the dissimilar material and takes a certain period of time, e.g., five minutes, to dissolve upon contact with stomach fluid may be employed. The coating can also be an environmentally sensitive coating, e.g., a temperature or pH sensitive coating, or other chemically sensitive coating that provides for dissolution in a controlled fashion and allows one to activate the device when desired. Coatings that survive the stomach but dissolve in the intestine are also of interest, e.g., where one desires to delay activation until the device leaves the stomach. An example of such a coating is a polymer that is insoluble at low pH, but becomes soluble at a higher pH. Also of interest are pharmaceutical formulation protective coatings, e.g., a gel cap liquid protective coating that prevents the circuit from being activated by liquid of the gel cap.

Identifiers of interest include two dissimilar electrochemical materials, which act similar to the electrodes (e.g., anode and cathode) of a power source. The reference to an electrode or anode or cathode are used here merely as illustrative examples. The scope of the present invention is not limited by the label used and includes the embodiment wherein the voltage potential is created between two dissimilar materials. Thus, when reference is made to an electrode, anode, or cathode it is intended as a reference to a voltage potential created between two dissimilar materials.

When the materials are exposed and come into contact with the body fluid, such as stomach acid or other types of fluid (either alone or in combination with a dried conductive medium precursor), a potential difference, that is, a voltage, is generated between the electrodes as a result of the respective oxidation and reduction reactions incurred to the two electrode materials. A voltaic cell, or battery, can thereby be produced. Accordingly, in embodiments of the invention, such power supplies are configured such that when the two dissimilar materials are exposed to the target site, e.g., the stomach, the digestive tract, etc., a voltage is generated.

In certain embodiments, one or both of the metals may be doped with a non-metal, e.g., to enhance the voltage output of the battery. Non-metals that may be used as doping agents in certain embodiments include, but are not limited to: sulfur, iodine and the like.

It is to be understood that this invention is not limited to particular embodiments or aspects described, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.

Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits,

ranges excluding either or both of those included limits are also included in the invention.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, representative illustrative methods and materials are now described.

All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference and are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.

It is noted that, as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.

As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present invention. Any recited method can be carried out in the order of events recited or in any other order which is logically possible.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

Accordingly, the preceding merely illustrates the principles of the invention. It will be appreciated that those skilled in the art will be able to devise various arrangements which, although not explicitly described or shown herein, embody the principles of the invention and are included within its spirit and scope. Furthermore, all examples and conditional language recited herein are principally intended to aid the reader in understanding the principles of the invention and the concepts contributed by the inventors to furthering the art, and are to be construed as being without limitation to such specifically recited examples and conditions. Moreover, all statements herein reciting principles, aspects, and embodiments of the invention as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Additionally, it is intended that such equivalents include both currently known equivalents and equivalents developed in the future, i.e., any elements developed that perform the same function, regardless of structure. The scope of the present invention, therefore, is not intended to be limited to the exemplary

embodiments shown and described herein. Rather, the scope and spirit of present invention is embodied by the appended claims.

What is claimed is:

1. A composition, comprising:

a pharmaceutical product comprising a pharmaceutically acceptable carrier; and

an ingestible event marker coupled to the pharmaceutical product, wherein the ingestible event marker comprises:

a control device; and

a partial power source comprising first and second electrodes formed of dissimilar electrochemical materials configured to contact a conductive fluid and generate a voltage to energize the ingestible event marker;

wherein the control device of the energized ingestible event marker is configured to modulate current flow through the conductive fluid, the modulated current flow defining a unique current signature associated with the ingestible event marker;

wherein the ingestible event marker of the composition is: coated with an external layer configured to delay activation of the ingestible event marker for a first period of time; and

positioned inside the pharmaceutically acceptable carrier, relative to a perimeter defined by the pharmaceutically acceptable carrier, to delay activation of the ingestible event marker for a second period of time, wherein the ingestible event marker is positioned proximate to the perimeter or proximate to a center of the pharmaceutically acceptable carrier based on an identity of the pharmaceutical product.

2. The composition according to claim 1, wherein the external layer comprises a homogeneous layer of a single material.

3. The composition according to claim 1, wherein the external layer comprises two or more distinct materials.

4. The composition according to claim 3, wherein the two or more distinct materials are present as a multilayer structure.

5. The composition according to claim 1, wherein the external layer is configured to provide conductive fluid passage through the external layer after contact of the composition with the conductive fluid.

6. The composition according to claim 1, wherein the external layer is further configured to protect the ingestible event marker in a dicing process.

7. The composition according to claim 1, wherein the external layer is configured to dissolve in five or more minutes after being in contact with the conducting fluid.

8. The composition according to claim 1, wherein the external layer is environmentally sensitive.

9. The composition according to claim 8, wherein the external layer is temperature sensitive.

10. The composition according to claim 8, wherein the external layer is pH sensitive.

11. The composition according to claim 10, wherein the external layer is insoluble at a first pH and soluble at a second pH.

12. The composition according to claim 1, wherein the ingestible event marker is secured inside the pharmaceutically acceptable carrier.

13. The composition according to claim 1, wherein the first and second electrodes of the ingestible event marker are coated with the external layer.

## 15

14. The composition according to claim 1, wherein the pharmaceutical product further comprises a pharmaceutical material, and wherein the external layer is further configured to prevent the ingestible event marker from being activated by the pharmaceutical material.

15. The composition according to claim 1, wherein the ingestible event marker is positioned proximate to the perimeter or proximate to the center of the pharmaceutically acceptable carrier further based on a desired activation delay between a time of initial ingestion and activation of the ingestible event marker.

16. A composition, comprising:

a pharmaceutical product comprising a pharmaceutically acceptable carrier; and

an ingestible event marker positioned inside the pharmaceutical product, wherein the ingestible event marker comprises:

a partial power source comprising first and second electrodes formed of dissimilar electrochemical materials, wherein the partial power source is configured to generate a voltage to energize the ingestible event marker upon contact with a conductive fluid; and

## 16

a control device configured to modulate current flow through the conductive fluid, wherein the modulated current flow defines a unique current signature;

wherein the ingestible event marker of the composition is:

coated with an external layer configured to at least one of delay activation of the ingestible event marker or protect the ingestible event marker; and

positioned relative to a perimeter defined by the pharmaceutically acceptable carrier to delay activation of the ingestible event marker, wherein the ingestible event marker is positioned proximate to the perimeter or proximate to a center of the pharmaceutically acceptable carrier based on an identity of the pharmaceutical product.

17. The composition according to claim 16, wherein the first and second electrodes of the ingestible event marker are coated with the external layer.

18. The composition according to claim 16, wherein the external layer is environmentally sensitive.

\* \* \* \* \*

专利名称(译)	带有部分电源的通信系统		
公开(公告)号	<a href="#">US10542909</a>	公开(公告)日	2020-01-28
申请号	US15/474811	申请日	2017-03-30
[标]申请(专利权)人(译)	普罗秋斯数字健康公司		
申请(专利权)人(译)	PROTEUS数字医疗，INC.		
当前申请(专利权)人(译)	PROTEUS数字医疗，INC.		
[标]发明人	ZDEBLICK MARK ROBERTSON TIMOTHY PIKELNY ALEKSANDR HAFEZI HOOMAN		
发明人	ZDEBLICK, MARK ROBERTSON, TIMOTHY PIKELNY, ALEKSANDR HAFEZI, HOOMAN		
IPC分类号	A61B5/07 H01Q1/27 A61J3/00 G06K7/10 A61B5/00 A61B5/1473		
CPC分类号	A61B5/4833 A61B5/0031 A61B5/4839 A61B5/073 A61B5/1473 A61B5/076 A61B5/07 A61B5/7282 A61B5/681 A61B5/6861 A61B5/0028 G06K7/10168 A61J3/007 H01Q1/273 Y10T29/49117 A61B2560 /0462 A61B2562/08 A61B2560/0214 A61B2562/162		
审查员(译)	WILSON，BRIAN		
优先权	PCT/US2006/016370 2006-04-28 WO 60/676145 2005-04-28 US 60/694078 2005-06-24 US 60/713680 2005-09-01 US 60/790335 2006-04-07 US		
其他公开文献	US20170265813A1		
外部链接	<a href="#">Espacenet</a>		

#### 摘要(译)

本发明的系统包括以不同材料形式的导电元件，电子部件和部分电源。一旦与导电流体接触，就会产生电势并完成电源，从而激活系统。电子组件控制不同材料之间的电导，以产生独特的电流信号。该系统可以用于各种不同的应用中，包括作为可摄入标识符的组件，例如可以在可摄入事件标记中找到的组件，例如，启用了药物信息学的药物组合物。

